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ABSTRACT 
The idiopathic inflammatory myopathies (IIM), shortly named myositis, is a group of 
heterogeneous and rare autoimmune diseases with the target tissue of skeletal muscle. It is 
not curable and affects the daily life of patients. The treatment of myositis is mainly 
glucocorticoids in combination with immunosuppressive agents. The incomplete response 
and common side effects of conventional treatment requires new therapies. The pathological 
mechanisms of myositis are still not known, however, it is widely accepted that both innate 
immunity and adaptive immunity contribute to the pathogenesis of myositis. 
 
T cells play an important role in the pathogenesis of myositis, which is also a promising target 
to develop novel treatment. The main aim of Project 1 and 2 was to investigate the effects 
of abatacept (CTLA4-Ig), a costimulatory modulator of T cells, on disease activity, 
expression of different molecules in muscle biopsies, and phenotypes of T and B cells in 
blood samples of adult patients with refractory dermatomyositis (DM) or polymyositis (PM). 
In this pilot study, we found that almost half of the DM and PM patients obtained 
improvement of disease activity after abatacept treatment and few side effects. The elevated 
number of FOXP3+ Tregs in repeated muscle biopsies indicates a positive effect of treatment 
in muscle tissue. CyTOF technology requires a larger patient cohort for discovery research 
and for immune-monitoring if the patients are clinically heterogeneous. Furthermore, 
CD4/CD8 ratio in circulation at time of active disease may be a predictor of response to 
abatacept treatment in patients with DM and PM. 
 
Type І IFN is also thought to be an important pathway involved in the pathogenesis of 
patients with DM and PM. In Project 3, we found evidence to support our hypothesis that 
CD66b+ neutrophils express LL-37, which may stimulate BDCA2+ pDCs to produce type I 
IFN (MxA) in muscle and skin samples of patients with DM and PM, regardless of short or 
long disease duration. The higher number of CD66b+ neutrophils and the association between 
neutrophils and MxA in patients negative for autoantibodies targeting RNA-binding proteins 
may suggest that our hypothesis is a potential alternative pathway to induce the elevated type 
І IFN in myositis patients without these autoantibodies. 
 
In project 4, we aimed to identify biomarkers in repeated muscle biopsies or blood samples, 
taken before and after conventional immunosuppressive therapy, to predict therapeutic 
response in patients with myositis. In this pilot study, we conclude that baseline biopsy, or 
monocyte profile did not predict long-term treatment response, but in the repeated biopsy 
taken within 1 year of immunosuppressive treatment, the lower number of macrophages 
(CD68+) seemed to predict a more favorable long-term response with regard to improved 
muscle strength. Furthermore, T cells in muscle biopsies were not affected by the 
conventional immunosuppressive therapy. This may indicate that repeated muscle biopsies 
provide additional information to guide immunosuppressive treatment. 
 
In conclusion, our findings provide more information about effects of treatment and 
pathologic immune mechanisms of myositis and strengthen the critical role of innate and 
adaptive immune response in the pathogenesis of myositis by investigation from different 
perspectives, which may provide basis to develop novel and effective therapies for patients 
with myositis. 
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1 INTRODUCTION 
The idiopathic inflammatory myopathies (IIM), briefly named myositis, is a group of chronic 
inflammatory diseases, with an incidence around 11 cases per million people per year [1, 2]. 
Muscle weakness is the main clinical manifestation, however, other organs are often involved 
like skin, lung, and the heart. Cardiovascular complications, interstitial lung disease (ILD), and 
cancer are common causes of death of myositis patients [3, 4]. Myositis in adults has for several 
years mainly included three subsets based on distinct clinical and laboratory characteristics. 
Dermatomyositis (DM) that occurs in both adults and children (juvenile dermatomyositis, 
JDM), with skin involvement and may be associated with cancer. Polymyositis (PM) mainly 
affects adults and is more common in women than men. Patients with sporadic inclusion body 
myositis (sIBM) are usually men over 50 years of age at disease onset and the myopathy is 
treatment resistant [1]. However, there are also other more recently suggested subgroups of 
myositis, such as clinically amyopathic dermatomyositis (CADM), immune mediated 
necrotizing myopathy (IMNM), anti-synthetase syndrome (ASS) and myositis with overlap 
syndrome [5]. 
1.1 CLINICAL AND LABORATORY FEATURES 
Proximal muscle weakness and low muscle endurance are common features of most patients 
with myositis. These symptoms can exist for weeks or months and in some individuals for 
years before diagnosis. The patients usually experience difficulties to conduct daily activities 
using the proximal muscle, like climbing stairs and combing hair. Swallowing problems may 
also be present. Some patients have difficulties lifting their heads while lying down due to 
weakness of the neck flexors. Ocular and facial muscles often remain normal [1, 6]. As the 
disorder progresses, the fine-motor movements using distal muscles can also be affected, which 
translates into difficulties with knitting and sewing, for instance. Muscle enzymes are released 
when muscle fibers suffer from degeneration and damage [1]. Creatine kinase (CK) as the most 
sensitive muscle enzyme could increase up to 50-fold (DM and PM) and below 12-fold (sIBM) 
compared to normal levels. Elevated levels of other enzymes like lactate dehydrogenase 
(LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) may also be 
observed [1]. Except for skeletal muscle, other organs like skin, lung, gastrointestinal tract, 
pharyngeal muscle, heart, and joints may also be involved and further cause 
limitations/disabilities of the patients.  
The histological characterization of most patients with myositis is the presence of inflammatory 
cells in skeletal muscle like T cells, B cells, macrophages, and dendritic cells (DCs) [7, 8]. Both 
CD4+ and CD8+ T cells can be present in muscle tissue of myositis patients but different 
patterns and localizations of T cells have been reported in different subgroups as described 
below. Figure 1 is a representative picture of immunohistochemistry staining of CD3+, CD4+, 
CD8+ T cells, and CD68+ macrophages in muscle biopsies from one patient with PM diagnosis. 
The distinct clinical and laboratory features of myositis are presented in Table 1. CD28null T 
cells of both CD4 and CD8 phenotypes are observed to dominate in the muscle biopsies of 
some patients with myositis [9]. The cytotoxicity targeting muscle fibers and resistance to 
apoptosis may contribute to the pathogenesis of myositis. Circulating autoantibodies are found 
in more than 50% of patients with myositis [10], including myositis specific autoantibodies 
(MSAs) and myositis associated autoantibodies (MAAs). Autoantibodies, especially MSAs, 
could correlate to specific clinical symptoms like anti-Jo-1 antibodies and the occurrence of 
ILD, and anti-Mi-2 antibodies with skin rash [11, 12], suggesting that autoantibodies are critical 
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in the development of clinical manifestations and immune pathogenesis of myositis. The 
presence of T cells in muscle biopsies, the involvement of specific HLA-DR genotype [13, 14], 
and the existence of autoantibodies in myositis patients indicate important roles of the adaptive 
immune system in the pathological mechanisms underlying myositis.  
1.1.1 Dermatomyositis (DM) 
Skin rash makes DM distinct from PM and sIBM. The typical skin rashes in DM patients are 
as follows: heliotrope discoloration rash on the eyelids; Gottron´s signs or papules on the body 
surface of joints e.g. fingers, knees, elbows. Other typical skin rash includes redness over the 
neck, upper chest (often in a V shape), shoulders (shawl sign) or the back [1]. Sunshine 
exposure may aggravate the skin rash [15]. Thickened and distorted cuticles and dilated 
capillary loops in fingernails may also be found in patients with DM and an increased incidence 
of cancer is also observed in patients with DM [1]. 
The muscle biopsies of DM patients are in typical cases characterized by inflammatory 
infiltrates surrounding blood vessels in perivascular and perimysial area, constituted primarily 
of CD4+ T cells, macrophages, and plasmacytoid dendritic cells (pDCs) [16]. Perifascicular 
atrophic muscle fibers are also observed in the muscle biopsies of patients with DM [1, 16]. 
Deposits of complement C5b-C9 and membrane attack complex (MAC) in vessel walls is also 
a distinct histopathological feature of DM [5]. In some cases the biopsy may look normal, and 
a normal muscle pathology does not exclude DM diagnosis. These histopathological features 
in muscle biopsies suggest involvement of immune mechanisms in patients with DM where 
micro-vessels could be a target of the immune reaction. 
1.1.2 Polymyositis (PM) 
Polymyositis (PM) is mostly seen in adult patients. By definition they do not have the DM skin 
rash. PM may have lasted for a period up to months before the patients realize they need the 
help from physicians. 
Invasion of inflammatory cells into non-necrotic muscle fibers is often regarded as one distinct 
feature of muscle biopsies from patients with PM. The inflammatory cells surrounding the non-
necrotic muscle fibers are primarily CD8+ T cells, CD4+ T cells, macrophages, and DCs [16]. 
Compared to DM, cytotoxic CD8+ T cells seem to contribute to the injury of muscle tissue of 
patients with PM as the perforin (protein involved in cell membrane pore formation ) in 
cytotoxic CD8+ T cells of patients with PM has been reported to be distributed towards the 
muscle fibers whereas the perforin in CD8+ T cells of patients with DM was distributed evenly 
in the cytoplasm [17]. The different observations of histopathological features suggest different 
immune mechanisms involved in patients with DM and PM. 
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Figure 1. Immunohistochemistry staining of inflammatory infiltrates in consecutive muscle 
biopsy sections of a patient with diagnosis of PM. The staining shows inflammatory cell 
infiltrates consisting of T cells and macrophages surrounding muscle fibers. (A) CD3 staining, 
(B) CD4 staining, (C) CD8 staining, and (D) CD68 staining. Original magnification is 250×. 
 
1.1.3 Sporadic inclusion body myositis (sIBM) 
Patients with sIBM are typically above 50 years old (more males than females, the ratio is 3:1) 
at onset with a slowly progressive muscle weakness distributed asymmetrically in not only 
proximal muscle but also distal muscle [1]. sIBM patients are liable to fall due to the weakness 
of quadriceps muscle in the early stage [1]. Besides the thigh muscle, finger flexor muscles, 
neck flexors, and pharyngeal muscles are also often affected [14]. sIBM progresses more 
slowly than DM and PM patients, up to years instead of months [1]. sIBM patients are easily 
to be misdiagnosed initially as PM due to the shared pattern of muscle weakness, endomysial 
inflammation in muscle biopsies, and absence of skin rash [14]. However, patients with sIBM 
are in general resistant to immunosuppressive therapy, which is a distinct feature of sIBM.  
Patients can be diagnosed as sIBM based on typical clinical features, but muscle biopsies are 
helpful in the diagnosis [14]. There are slit-like vacuoles (rimmed vacuoles) with basophilic 
granular inclusions inside muscle fibers. There may be also accumulated amyloid deposits 
inside muscle fibers, which is one histological characteristic of muscle biopsies from sIBM 
patients. The endomysial inflammatory cells and the degenerative features indicate the 
involvement of both immune and non-immune mechanisms in the pathogenesis of sIBM.  
 
 
 4 
 
Table 1. The distinct clinical and laboratory features of myositis. 
 DM PM sIBM 
Age Adults and children Adults > 18 years old Adults > 50 years old 
Gender  Females:males (3:1) Females:males (3:1) Females:males (1:3) 
Skin rash yes no no 
Affected muscle Proximal; 
symmetrical 
Proximal; 
symmetrical 
Distal and proximal; 
asymmetrical 
Progress period Weeks to months Weeks to months Months to years 
CK level Above 50-fold Above 50-fold Below 12-fold 
Resistant to IS 
treatment 
no no yes 
Histological features 
in muscle biopsy 
Perimysial and 
perivascular 
inflammation; 
Perifascicular 
atrophy; 
Deposits of C5b-C9 
and MAC in vessel 
walls;  
MHC class І 
expressed in muscle 
fibers 
 
Endomysial infiltrates 
surrounding non-
necrotic muscle 
fibers; 
MHC class І 
expressed in muscle 
fibers 
Endomysial infiltrates 
surrounding non-
necrotic muscle 
fibers; 
Rimmed vacuoles; β-
amyloid deposits 
inside muscle fibers; 
MHC class І 
expressed in muscle 
fibers 
CK: creatine kinase; C5b: Complement protein 5b; C9: Complement protein 9; MAC: 
membrane attack complex; IS: immunosuppressive treatment; MHC: major histocompatibility 
complex 
 
1.2 DIAGNOSITIC AND CLASSIFICATION CRITERIA 
1.2.1 Bohan and Peter criteria 
There are no generally accepted criteria for diagnosis of DM and PM, while there are generally 
accepted principles. The most often used criteria were proposed by Bohan and Peter [18, 19]. 
Bohan and Peter criteria were developed to be both diagnostic and classification criteria. 
The Bohan and Peter criteria for DM and PM consist of five items.  
1. Symmetrically distributed muscle weakness of limb-girdle and anterior neck flexors. 
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2. Characteristic histological features in muscle biopsies: necrosis, phagocytosis, regeneration 
features, perifascicular atrophy and degeneration of muscle fibers, different sizes of muscle 
fibers, perivascular inflammatory infiltrates, and increased connective tissue. 
3. Increased muscle enzymes especially CK in serum. 
4. Electromyography shows characteristic features. 
5. Typical skin manifestations of DM like the heliotrope discoloration on the eyelids and 
Gottron’s sign.  
Notably other causes of myopathies need to be excluded.  
There are 3 subgroups classified from DM and PM, including definite DM/PM, probable 
DM/PM, and possible DM/PM.  
For DM classification skin rash is mandatory and then DM is considered as definite when three 
of criteria 1-4 above are achieved. With two criteria met, it is considered as probable DM and 
as possible DM when one criterion in addition to skin rash is present. The diagnosis is 
confirmed as definite PM when the criteria 1-4 are met. The diagnosis of probable PM is 
considered when three criteria are fulfilled. With only two criteria fulfilled, the diagnosis is 
possible PM. For the diagnosis of PM, the skin manifestations (rash) are not included.  
1.2.2 Griggs criteria 
Diagnostic criteria for sIBM were first proposed by Calabrese and colleagues in 1987 [20]. 
After that, different researchers suggested other different criteria. However, the more 
frequently used diagnostic criteria were proposed by Griggs’ group [21]. These criteria have a 
strong emphasis on muscle biopsy features with a high specificity but low sensitivity.  
The criteria include 6 main points: 
1. Duration of illness must last at least 6 months. 
2. Age at disease onset at least 30-year-old. 
3. Muscle weakness must have effect on proximal and distal muscles of arms and legs and 
patients must display at least one of the following features: 
1) Finger flexor weakness. 
2) Wrist flexor weakness is more serious than wrist extensor weakness. 
3) Quadriceps muscle weakness. 
4. Serum CK less than 12 times normal 
5. Muscle biopsy with the following features: 
1) Inflammatory myopathy characterized by mononuclear cell invasion of non-necrotic 
muscle fibers. 
2) Vacuolated muscle fibers. 
3) Intracellular amyloid deposits or tubulofilaments by electron microscopy. 
 6. Electromyography must display consistent features of inflammatory myopathies. 
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When there are typical findings in muscle biopsy (criterion 5 above), definite sIBM is diagnosed 
irrespective of other clinical features. In contrast, the diagnosis of possible sIBM is considered 
when the characteristic clinical and laboratory features are present even with absence of the 
typical histopathological characteristics in muscle biopsies. 
1.2.3 2017 EULAR-ACR classification criteria 
The Bohan and Peter criteria were published in 1975 and Griggs’ criteria for sIBM were 
proposed in 1995 [18, 19, 21]. During the last decades, much progress has been made in the 
field of myositis and has offered some new perspectives to classify myositis, like inclusion of 
extramuscular manifestations other than skin rash such as ILD and autoantibodies [5]. The 
increased knowledge and the limitations of old criteria prompted myositis experts to work 
together to issue new classification criteria. 2017 European League Against 
Rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile 
idiopathic inflammatory myopathies and their major subgroups were proposed [22, 23]. There 
are several merits of the new criteria [22, 23]. Firstly, the variables that classify a patient as 
having myositis are data driven based on comparisons between cases and comparator cases. 
Secondly, each variable is given a score based on statistical analysis, and the total value of 
adding all the scores will decide the probability of myositis. This quantitative way is easier to 
be put into practice. Thirdly, the score system includes two options - with muscle biopsies or 
not, which is more flexible than previous criteria. Fourthly, subgrouping of patients classified 
as having myositis is based on a classification tree. This criteria could divide myositis patients 
into JDM, DM, CADM, PM, and sIBM. Fifthly, a web-calculator has been developed to help 
investigators to easily calculate the values. In conclusion, the new classification criteria are 
flexible and easily to use for investigators. 
1.3 IMPROVEMENT CRITERIA 
1.3.1 IMACS criteria 
Two improvement criteria will be introduced here and both of them are based on the 
International Myositis Assessment and Clinical Studies Group (IMACS) core set measures 
[24]. 
The core set measures of IMACS include six points: 
1. Physician´s global disease activity, measured by Likert or visual analogue scale (VAS). 
2. Patient´s global disease activity, measured by Likert or VAS. 
3. Manual muscle test (MMT)-8, which is used to test muscle strength. 
4. Health Assessment Questionnaire of activities of daily living (HAQ) 
5. Serum levels of muscle enzymes. At least two of the following muscle enzyme activities: 
CK, LDH, ALT, and AST. 
6. Extra muscular score: evaluation of constitutional, cutaneous, gastrointestinal, articular, 
cardiac, and pulmonary activity by using Myositis Disease Activity Assessment Tool 
(MDAAT). MDAAT include two methods: Myositis Disease Activity Assessment Visual 
Analogue Scales (MYOACT) and Myositis Intention to treat Activity Index (MITAX). 
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The generally accepted improvement criteria are IMACS preliminary Definition of 
Improvement (DOI). DOI is defined as any 3 of 6 core set measures improved ≥ 20%, with no 
more than 2 (not including MMT-8) worsening by ≥25% [24]. 
1.3.2 2016 IMACS Improvement Criteria 
A new set of improvement criteria, 2016 American College of Rheumatology/European 
League Against Rheumatism criteria for minimal, moderate, and major clinical response in 
adult dermatomyositis and polymyositis, were published based on the core set measures of 
IMACS describing myositis disease activity [24, 25]. Total improvement score (range 1-100) 
is calculated by adding scores of the six core set disease activities of IMACS, and ≥ 20, ≥ 40, 
≥ 60 represents minimal, moderate, and major improvement, respectively. This improvement 
criteria use a continuous quantitative definition, which not only defines patients qualitatively, 
but also quantitatively [25]. The exact scores representing the improvement of patients could 
also be used to calculate the correlations between the improvement and other clinical or 
molecular variables. Myositis experts voted to agree on the new definition also to lay the 
foundation of general application of these criteria in the future. These criteria are also suitable 
for both adult DM/PM and also JDM patients except for different thresholds, which help the 
parallel comparisons of different studies [25].  
1.4 TREATMENT 
The primary treatment of myositis patients is glucocorticoids in combination with 
immunosuppressive agents. However, few randomized controlled studies have been performed 
in patients with myositis, and treatment recommendations are mainly based on open studies 
and case reports due to the rarity of the disease, the heterogeneity of myositis and the up to 
recently lack of widely accepted classification criteria and improvement criteria. In general, an 
incomplete response and unwanted side effects are often observed. Thus, more effective and 
safer therapy is clearly needed. Exercise was introduced due to the beneficial effects and minor 
adverse effects [26]. In addition, biological treatments targeting specific pathogenic cells and 
molecules have recently been tested but few studies are available to support treatment 
recommendations. Most of the exercise studies have shown efficacy and been well tolerated by 
patients with myositis. Whereas the reports of biological therapies often are small and have 
shown inconsistent results. Further larger, randomized, controlled, and homogeneous studies 
are clearly required to confirm the results. Moreover, the unclear molecular mechanism of 
myositis also put up obstacles to develop novel and effective therapies.  
1.4.1 Conventional treatment 
Glucocorticoids, first applied in 1950s, are still first line agents but treatment outcome is not 
satisfactory and side effects are common [27]. Hence, immunosuppressants (methotrexate or 
azathioprine as first line therapy) are recommended in combination with glucocorticoids either 
to reduce the dose of glucocorticoids or to enhance the immunosuppressive effect [28]. Some 
patients with DM and PM could be responsive to the treatment and get improvement of muscle 
performance, but most patients fail to recover their muscle strength. In some patients the 
inflammatory infiltrates in muscle tissue may persist over several years despite high doses of 
immunosuppressive treatment. If methotrexate or azathioprine are not tolerated or if patients 
do not improve, cyclosporine A, high dose intravenous immunoglobulins (IVIGs) [29], 
cyclophosphamide, or mycophenolate mofetil (MMF) could be applied (second line therapy) 
[28]. But still not all patients are responsive to these therapeutic options. Several explanations 
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could be considered. Firstly, the application of the therapies is mainly according to the case 
reports from literature due to lack of large, randomized, and controlled trials. Secondly, due to 
limited understanding of the molecular mechanisms of the disease conditions, the therapies are 
not specific which increases the risk of unspecific adverse events such as bone marrow 
depression and increased risk of infections. Lastly, several factors could affect the response of 
patients to the treatment like the autoantibody profiles and the duration since time of diagnosis 
[30].  
sIBM is even more difficult to treat and there are no data about beneficial effects of 
pharmacological treatment in sIBM [28]. Randomized placebo-controlled trials of large patient 
groups, long duration of treatment, more useful validation, better outcome measures are highly 
warranted to investigate the effects of different therapies on the progression of sIBM [31].  
1.4.2 Biological treatment 
Biological therapies have been introduced with great success to treat patients with rheumatoid 
arthritis (RA) [32]. Furthermore, through evaluating the effects of biological treatments on 
myositis patients, we could also investigate the pathogenesis of myositis at the same time. As 
most of the biological therapies specifically target distinct cells or cytokines present in the 
disease conditions, the administration of these treatments could block or interrupt the functions 
of cells and cytokines. If the interruption or blocking of a specific molecule is followed by 
clinical improvement, this might support that the associated molecular pathways are associated 
with the pathogenesis of myositis. The predominant roles of CD28null T cells and the 
association with HLA-DR phenotypes suggests the importance of T cells in the disease 
pathogenesis, which makes specific therapy targeting T cells activity very interesting. Other 
interesting targets include B cells and type І IFN. A detailed introduction is given based on the 
molecular targets of the biological treatments. Several biological treatments to myositis are 
listed in Table 2.  
1.4.2.1 B cells 
Rituximab specifically depletes CD20+ B cells [28]. Reasons for using B cell deletion therapy 
in patients with myositis are the observed B cells and plasma cells in muscle tissue and the 
presence of autoantibodies in about over 50% of patients with myositis [10, 16]. A randomized, 
double-blind, placebo-controlled trial, “Rituximab in Myositis” (RIM), has been conducted to 
investigate the effect of rituximab in 200 patients with refractory DM, JDM, and PM. Patients 
were randomized into early treatment or 8 weeks later treatment. Although no significant 
difference was observed between the two groups, still 83% of the patients improved as defined 
by IMACS improvement criteria [33]. A post hoc analysis of these patients revealed that 
patients with anti-Jo-1 or anti-Mi-2 antibodies were more liable to respond to rituximab 
compared to the patients without these autoantibodies [34]. Rituximab has been suggested by 
some investigators as one of options of third-line therapies [28] but further investigations are 
recommended to demonstrate significant efficacy compared to placebo. 
1.4.2.2 T cells 
T cells account for a large proportion of the inflammatory infiltrates in muscle tissue of patients 
with myositis [16], which makes T cell blockade a logically potential therapy. Abatacept 
(CTLA-4Ig) is a recombinant fusion protein composed of the extracellular part of human 
CTLA-4 and a fragment of the Fc region of human IgG1, which binds specifically to 
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costimulatory molecules B7 on antigen presenting cells (APCs) and hence block the CD28-
mediated activation of T cells. Abatacept has been approved to be used in RA patients. 
Abatacept proved useful in one female patient with PM resistant to conventional treatment [35]. 
In another case report, abatacept also showed efficacy in a female patient with severe myositis 
overlap syndrome, who was refractory to immunosuppressive treatment and two biological 
(rituximab and tocilizumab) agents [36]. 
1.4.2.3 Lymphocyte cells 
Alemtuzumab is a human anti-CD52 antibody, also named as CAMPATH-1. CD52 is a 
polyprotein on the surface of T cells, B cells, monocytes, and natural killer (NK) cells [37]. 
Alemtuzumab has shown promising effects on patients with RA and multiple sclerosis (MS) 
[38]. One 48-year-old female patient with refractory PM received treatment of alemtuzumab 
and got a relief of her muscle weakness for several weeks, and the patient could thereafter 
respond to a combination of MMF and prednisolone which was not useful previously [39]. 
Thirteen sIBM patients who received alemtuzumab for four days experienced improved muscle 
strength after six months follow-up but returned to conditions before treatment after twelve 
months. These data are interesting in this refractory subset of myositis suggesting that 
alemtuzumab may be a potential drug for sIBM patients [38]. 
1.4.2.4 TNF-α and TNF-α receptor 
The presence of tumor necrosis factor (TNF)-α mRNA and protein in muscle biopsies of 
myositis patients imply the possibility that TNF-α is involved in the pathogenesis of myositis 
[40, 41], further suggesting that TNF-α is a potential target to design specific therapy for 
myositis. However, several case studies reported that TNF-inhibitor could also induce the 
occurrence of DM in patients with RA [36]. Thus, the efficacy and safety of TNF-inhibitor 
therapy in patients with myositis is controversial. Three biological drugs available to block 
TNF-α are discussed in patients with myositis here: infliximab, adalimumab, and etanercept.  
Infliximab is a chimeric monoclonal antibody targeting TNF-α. Infliximab has shown 
beneficial effect in patients with RA [42]. A few early case reports suggested that infliximab 
could be an effective treatment for patients with myositis [42, 43]. However, an open label pilot 
study with 13 refractory myositis patients did not show efficacy of infliximab [41]. On the 
contrary, some patients flared and the flares were associated with increased type І interferon 
(IFN) activity in peripheral blood, suggesting that anti-TNF blockade using antibodies may 
activate the innate immune system leading to IFN-α activity which could induce increased 
muscle inflammation in patients with myositis [41]. An open-label trial cooperated by several 
European centers was stopped preterm due to difficulties to include target myositis patients, 
high termination rate because of disease progression, and the development of unwanted adverse 
effects [44]. These studies indicate that application of infliximab for treating myositis might 
only be suitable for a minority of patients with myositis. 
Adalimumab is a human monoclonal anti-TNF-α antibody. A 48-year-old female DM patient 
with ILD was treated by adalimumab due to the minor improvement after the treatment of 
glucocorticoids and immunosuppressive agents. After three months, the muscle weakness, skin 
rashes, and ILD were improved [45]. Adalimumab could therefore be a useful drug for DM 
patients with ILD and resistant to conventional treatment, but larger trials are needed. 
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Etanercept is a fusion protein of TNF receptor with a constant portion of human IgG1. 
Etanercept was efficient in a 50-year-old female patient with PM leading to decreased serum 
level of LDH and increased muscle strength [46]. In a pilot study including new onset patients 
with DM, etanercept or placebo was added in combination with prednisone. There was no 
recorded difference in adverse events between treatment-group and placebo-group, and half of 
the patients in the treatment-group successfully decreased the dose of prednisone which was 
the primary endpoint in this study [47]. Another pilot study including sIBM patients treated by 
etanercept for an average time of 17 months showed improved grip strength after 12 months 
[48]. Considering the potential effects and the few side effects in new onset patients with DM 
and with the observed distal muscle improvement in sIBM patients, etanercept may be worth 
to be tested in a larger clinical trial. 
1.4.2.5 Type І IFN 
The overexpression of type І IFN signature in peripheral blood of patients with DM and PM 
and the correlation between type І IFN-inducible gene signature score and clinical disease 
activity render type І IFN an attractive candidate drug target [49]. A phase 1b randomized, 
double-blinded, multicenter trial including fifty-one patients with DM and PM has been 
conducted, showing that sifalimumab (anti-IFN-α monoclonal antibody) successfully 
decreased around 50% of the IFN gene signature in blood and muscle compared to placebo 
group, and patients with ≥ 15% improvement of MMT-8 had higher level of neutralization of 
type I IFN gene signature compared to patients with < 15% MMT-8 improvement [50]. 
However, a larger randomized blinded study is required to confirm its efficacy in patients with 
myositis or subgroups of myositis. 
1.4.2.6 IL-6 
Interleukin (IL)-6 is a multifunctional cytokine involved in many different immune responses, 
like stimulating the production of antibodies and the development of effector T cells. It is 
secreted by immune cells, endothelial cells, and also muscle fibers [51, 52]. In chronic 
inflammatory conditions, elevated IL-6 in circulation could result in muscle atrophy [52]. 
Tocilizumab is an IL-6 receptor antagonist, which has been approved for use in patients with 
RA in about 70 countries [53]. IL-6 expression levels in serum of DM patients correlated 
significantly with disease activity in one study [54]. Thus, there is data to support a role of IL-
6 in the pathogenesis of myositis, in particular in the subset with DM. A randomized, multi-
center, placebo-controlled pilot trial is in the stage of recruiting participants with the 
sponsorship of the University of Pittsburgh (Clinical tirals.gov). 
1.4.2.7 IL-1 
IL-1α and IL-1β are consistently expressed in muscle tissue by inflammatory cells of patients 
with myositis but not in healthy controls, and IL-1 receptors are overexpressed in the 
sarcolemma and nuclei of muscle fibers, endothelial cells, and inflammatory cells of patients 
with myositis compared to healthy controls [55]. Anakinra is a recombinant version of the IL-
1 receptor antagonist. A small pilot study of four sIBM patients treated with anakinra did not 
observe any improvement of muscle strength [56]. Another open label study including 15 
patients (DM, PM, and sIBM) suggested that some refractory patients with myositis could be 
responsive to anakinra as seven patients represented response based on IMACS criteria [57]. 
Thus, anakinra is a promising therapy in myositis, but still requires confirmation in a larger 
study. 
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Table 2. The information of several biological treatments. 
Biological 
agent 
Composition and target Trade name Trial in myositis 
Rituximab Monoclonal antibody 
against CD20 on B cells 
Rituxan/ 
Mabthera 
Randomized, placebo trial 
[33] 
Abatacept A fusion protein of CTLA-
4 and a constant domain of 
human IgG1 
Orencia Case reports [35, 36] 
 
Alemtuzumab Monoclonal antibody anti-
CD52 
Campath-1H Case reports [38, 39] 
Infliximab Chimeric monoclonal 
antibody anti TNF-α 
Remicade Case reports [42, 43], pilot 
study [41] 
Adalimumab Fully human monoclonal 
antibody against TNF-α 
Humira Case report [45] 
Etanercept A fusion protein of TNF 
receptor with a constant 
portion of human IgG1 
Enbrel Case report [46], pilot 
studies [47, 48] 
Sifalimumab Monoclonal antibody 
against IFN-α 
Sifalimumab Phase 1b clinical trial [50] 
Tocilizumab IL-6 receptor antagonist Roactemra 
/Actemra 
Ongoing Preparation for 
double-blind, controlled trial 
(Clinical tirals.gov)  
Anakinra IL-1 receptor antagonist Kineret Open pilot studies [56, 57] 
    
1.4.3 Exercise 
Except for the above discussed pharmacological therapies, physical exercise has turned out to 
be an effective therapy in combination with immunosuppressive treatment, for patients with 
DM and PM. For sIBM, there is less data available on the efficacy of exercise. Eleven patients 
with DM and PM exercised according to a 12-week resistive home exercise program in 
combination with conventional immunosuppressive treatment, with improved muscle function 
and quality of life without causing more inflammation [26]. A multicenter randomized 
controlled study displayed reduced disease activity and improved muscle performance in 
patients with DM and PM undergoing a 12-week endurance exercise compared to patients 
without exercise intervention [58]. An open study including 7 patients with sIBM showed 
improved muscle improvement and function with minor elevated serum CK level after a 16-
week home-based exercise program [59]. The underlying molecular mechanism of the 
observed beneficial effects of exercise in patients with myositis is not known. DM and PM 
patients who participated in a 12-week endurance training showed elevated aerobic capacity 
and muscle mitochondrial enzyme activities [60], as well as associations between maximal 
oxygen uptake (VO2 max) and physical function [58]. Furthermore, the overexpression of genes 
associated with capillary growth and mitochondrial genesis and increased number of capillaries 
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in muscle biopsies were also observed in DM and PM patients, suggesting that increased 
aerobic metabolism pathway might be one possible mechanism [61]. 
1.5 IMMUNE MECHANISMS 
Even though more knowledge of the pathological mechanisms of myositis has developed over 
the past decades, the detailed molecular mechanisms are still not clear. The shared clinical and 
histopathological features in muscle tissue suggest shared pathogenesis of some subsets of 
myositis patients, however, the specific characters of each subset also imply heterogeneity of 
the mechanisms between different subgroups of myositis. The involvement of immune-
associated genes, presence of inflammatory cells and cytokines, and autoantibodies in myositis 
suggests the important roles of immune system in the pathogenesis of myositis. 
1.5.1 Genetic risk factors 
The human leukocyte antigen (HLA), named major histocompatibility complex (MHC) in 
vertebrates, is thought to be a major genetic factor for myositis [62]. A genome-wide 
association study (GWAS) of 1710 myositis patients found that multiple alleles composed of 
HLA 8.1 ancestral haplotype (8.1AH) could virtually cover all the genetic risk factors of 
phenotypes studied in white population, however, different alleles showed different 
associations to different subsets of myositis. HLA-DRB1*03:01 alleles associated with JDM 
and DM whereas HLA-B*08:01 with PM and myositis patients with positivity of anti-Jo-1 
antibodies [13]. Another multicenter study confirmed the strongest association of 8.1AH region 
but found that HLA-DRB1*03:01 was more associated with PM and HLA-B*08:01 was more 
associated with DM [63]. Serotype of myositis specific autoantibodies seems to be stronger 
associated with certain HLA-DR genotypes than the traditional subgroups DM, PM, and IBM. 
Thus another study showed that HLA-DRB1*11:01 was related to an increased risk of anti-
HMGCR antibody-positive necrotizing autoimmune myositis in Caucasian and African 
Americans [64]. PTPN22 was another strong genetic factor besides HLA, especially associated 
with PM [63]. Other loci, UBE2L3, CD28, TRAF6, and STAT4 have also shown significant 
associations with myositis [63]. The results of a high-resolution HLA-DRB1 genotyping of 
sIBM patients in an Australian cohort showed that different regions in HLA-DRB1 were 
associated with sIBM, in which HLA-DRB1*03:01 allele and the HLA-DRB1*03:01/*01:01 
diplotype were the highest associated loci, indicating that HLA-DRB1 was a genetic factor in 
sIBM [65]. The associations with HLA-DR loci support the hypothesis of involvement of the 
adaptive immune system in patients with myositis as the major role of the HLA-DR molecule 
is to present antigen to CD4+ T cells. 
1.5.2 Environmental risk factors 
1.5.2.1 UV-light and Vitamin D 
An interesting observation is the increased prevalence of some autoimmune diseases with 
latitude, suggesting that ultraviolet (UV) radiation may be involved in the pathogenesis of 
autoimmune diseases [66]. UV light is a strong environmental contributor to DM and the subset 
of DM with anti-Mi-2 antibodies [67], which is mainly observed in females [68]. After short 
time exposure of UV light, an association was found between UV exposure and anti-p155/140 
antibodies in JDM patients [69]. 
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Vitamin D (cholecalciferol) is mainly synthesized in the skin with exposure of UV light or it 
could be obtained by food [70]. Cholecalciferol binds with the vitamin D binding protein (DBP) 
and moves into liver, where cholecalciferol is converted into 25(OH)D3 by enzymes [70]. Then 
25(OH)D3 enters into circulation and is transferred into the kidney, where is converted into 
1,25(OH)2D3. 1,25(OH)2D3 is the active type of vitamin D [70]. 
To avoid the disturbance of vitamin D from food, the level of 25(OH)D3 in serum is mainly 
used as a measurement to investigate the associations with autoimmune diseases [70]. Low 
serum levels of 25(OH)D3 was found in patients with autoimmune diseases like RA and 
systemic lupus erythematosus (SLE). These low serum levels correlated to high disease activity 
[70]. 
LL-37 is an anti-microbial peptide with the function of defending against bacteria. LL-37 could 
also modulate pro- and anti-immune response including activation of type I IFN system [71]. 
The expression of LL-37 could be regulated by different factors like vitamin D [72], which is 
also an important inducer of the gene expression of LL-37 [73]. Different relationships between 
serum levels of 25(OH)D3 and LL-37 were reported in different diseases [74-76]. Serum levels 
of 25(OH)D3 in myositis patients with short time of disease duration was lower compared to 
healthy controls, with a higher expression of LL-37 compared to healthy controls [77]. A 
deeper investigation between the relationship of 25(OH)D3, LL-37, and the type І IFN system 
would be interesting and might help understand the pathophysiology of myositis and might add 
information on LL-37 as a potential trigger mechanism for the type I IFN system known to be 
activated in some patients with myositis. 
1.5.2.2 Infections 
Infections are interesting environmental triggers of autoimmune diseases according to 
epidemiology reports and experiments in mouse model. However, a direct association between 
specific infections and autoimmune diseases has not been found to date [78]. Several 
hypothesized mechanisms have been proposed that speculate how infections may induce 
autoimmunity, such as (1) “molecular mimicry”, in which epitopes of a pathogen are similar 
to that of self-antigens; (2) “bystander activation of autoreactive cells”, in which autoreactive 
cells with low affinity to self-antigens may be further activated by infections [79]. The 
involvement of these mechanisms with the occurrence of autoimmune diseases still require 
further investigations. 
Virus is the major infectious agent implicated in the onset of autoimmune diseases. Some 
viruses have been detected in patients with autoimmune diseases like multiple sclerosis and 
type I diabetes, but again, the evidence of a direct link to the autoimmune disease is still lacking 
[80]. It has been reported of some possible associations between some viral infections and 
specific types of myositis, like Human Immunodeficiency Virus (HIV) in DM, Human T-cell 
lymphotropic Virus Type 1 (HTLV-1) in sIBM, Epstein-Barr virus (EBV) and Human 
Cytomegalovirus (HCMV) in DM and PM, Hepatitis C virus (HCV) and Hepatitis B virus 
(HBV) in PM [81-85]. However, no direct association between infections with viruses and 
myositis etiology has been properly demonstrated. 
1.5.3 Innate immunity 
The innate immune system serves as the first line of defense to combat the invasion from 
outside pathogens, which reacts quickly and efficiently. One of the major differences between 
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innate immunity and adaptive immunity is the unspecific recognition of the pathogens. Most 
bacteria and viruses share a structure called pathogen associated molecular patterns (PAMPs), 
which are essential to the survival of the pathogens. PAMPs are not expressed in eukaryotes. 
The pathogen recognition receptors (PRRs) expressed by immune cells bind to PAMPs and 
initiate the activation of immune cells to kill the invading microbes. PRRs could also bind to 
damage associated molecular patterns (DAMPs) secreted by necrotic cells, leading to immune 
response and also repair processes [86]. 
PRRs can be found both on the surface of cells, organelles, and in the cytoplasm of different 
immune cells. The different types of PRRs own different functions. Here, Toll-like receptors 
(TLRs) is taken as an example. TLRs are expressed on the cell surface and also in the 
endosome. When TLRs bind to the PAMPs on the extracellular surface of microbes, two of 
most important downstream transcriptional factors: nuclear factor κB (NF-κB) and interferon 
regulator factors (IRFs) are activated. NF-κB stimulates the production of various cytokines 
like TNF-α, IL-1, and IRFs could induce the generation of type І IFN. These cytokines could 
help kill microbes and maintain the host defense [86]. 
The main components of innate immunity are mast cells, neutrophils, monocytes/macrophages, 
dendritic cells, NK cells, and complement proteins. Mast cells are present in resident tissue 
with abundant cytoplasm granules with histamine inside. Once mast cells recognize a pathogen, 
histamine is released, which will cause vasodilation and enhance vascular permeability 
promoting the recruitment of immune cells to the infected tissue. Neutrophils are the first cell 
type to respond to pathogens, but they can only survive for some hours in the tissue. Monocytes 
are less abundant in circulation and become macrophages when entering infected tissue. 
Neutrophils and monocytes/macrophages are two phagocytes which engulf and destroy 
pathogens and are recruited into infected sites when activated. Activated dendritic cells can 
release different cytokines and are important to connect innate immunity and adaptive 
immunity. NK cell is a type of cytotoxic lymphocytes which have the ability to recognize viral-
infected cells or stressed cells in the absence of antibodies or MHC molecules, allowing for a 
much faster immune reaction compared to T cells. Once activated by pathogens, NK cells work 
to control viral infections by secreting IFN-γ and TNF-α, which will promote the activation of 
macrophages leading to secretion of type І IFN, IL-12, and IL-15. These cytokines will in turn 
enhance the activation and function of NK cells. Complement proteins are mainly circulating 
proteolytic enzymes, which are activated by three different pathways: classical pathway, 
alternative pathway, and lectin pathway. Classical pathway is activated by the binding of 
antibodies so it is more involved in adaptive immunity. The activation of complement system 
could help phagocytes recognize and kill microbes via opsonization, recruit more cells to the 
resident site, and form MAC on the membrane of microbes leading to the lysis and apoptosis 
of microbes [86]. 
When a pathogen like bacteria invades our body and enters into the tissue, the resident mast 
cells recognize the PAMPs on the surface of the invading pathogen and then release histamine, 
causing dilation and elevated permeability of the vessel in the tissue. The resident dendritic 
cells and macrophages also recognize PAMPs and secret cytokines and chemokines, which 
also increase the vascular permeability and attract more immune cells into the infected tissue. 
Then neutrophils and monocytes in circulation cross through the vessel wall and enter the 
tissue. Neutrophils and macrophages could engulf and kill pathogens. The complement 
proteins also help enhance inflammation and phagocytosis [86]. The presence of different 
components of innate immune response like macrophages, complement proteins, and type I 
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IFN in muscle biopsies of patients with myositis suggest a critical role of innate immunity in 
patients with myositis. 
1.5.3.1 Eosinophils, macrophages, and complement proteins – relationship with myositis 
Different components involved in innate immunity were found present in the inflammatory 
environment of myositis. Eosinophils were mainly observed in endomysial, intra- and 
perivascular regions of muscle biopsies from DM, PM, and sIBM patients, and in higher 
numbers than those observed in healthy controls, suggesting that eosinophils might play a role 
in the pathogenesis of myositis [87]. Macrophages are present in muscle biopsies of patients of 
all subtypes of myositis but the expression pattern and localization may vary between different 
subsets of patients with myositis [88]. Furthermore, the differentiation pattern may vary 
between subsets of patients [88]. A subgroup of macrophages with expression of 25F9, a late-
activation marker, was co-localized with inducible nitric oxide synthetase (iNOS) and tumor 
growth factor (TGF)-β in muscle biopsies of DM and PM patients, indicating the contribution 
of late activated macrophages to the pathogenesis of DM and PM [89]. The observation of 
deposits of C5b-C9 and MAC in vessel walls suggest the involvement of complement system 
in the pathogenesis of DM. 
1.5.3.2 IFN – relationship with myositis 
Type І IFN is an important cytokine involved in the innate immune mechanism that has in 
particular been demonstrated in patients with DM, but also in patients with some autoantibodies 
targeting RNA-binding proteins like anti-Jo-1 antibodies [90, 91]. Type І IFN induced genes 
are up-regulated in peripheral blood samples of patients with DM and PM, and the 
overexpression of these genes showed positive correlation to the disease activity of DM and 
PM patients [49, 92, 93]. Several type І IFN regulated proteins overexpressed in serum 
correlated significantly to levels of muscle enzymes of DM patients [93]. Type І IFN signature 
has been observed in muscle and skin biopsies of DM patients, and also the expression of type 
І IFN secreted protein, myxovirus resistance protein A (MxA), and the main I IFN producer, 
pDC expressing BDCA-2 [90, 94].  
Autoantibodies, normally connected to the adaptive immune system, may be a possible inducer 
of type І IFN in both DM and PM [95], in line with the discoveries in patients with SLE [96]. 
However, DM patients without autoantibodies also showed increased MxA expression in 
muscle tissue, indicating the existence of type І IFN induction molecules other than 
autoantibodies [95]. TLR-7 and TLR-9 identified in inflammatory cells were found to co-
localize with BDCA-2 positive cells, which have been observed in muscle tissue of patients 
with DM/PM, suggesting their involvement in the production of type І IFN [97]. 
Expression of TLR-3 and retinoic acid inducible gene І (RIG-І), both inducers of type I IFN, 
was observed mainly in the atrophic fibers in the perifascicular areas of muscle biopsies of DM 
patients [97]. Type І IFN induced protein interferon-stimulated gene 15 (ISG15) was 
significantly upregulated in muscle biopsies of patients with DM and mainly found in the 
perifascicular atrophic muscle fibers [98], which may suggest the contribution of type І IFN to 
the atrophy of muscle fibers of DM patients. Type І IFN not only mediates the innate immunity, 
but also triggers a cascade of adaptive immunity response by recruiting and regulating different 
lymphocytes and cytokines [99]. Type I IFN attracts CXCR3+ lymphocytes and this has been 
identified in skin biopsies of DM patients [94]. Type І IFN also promotes the activity of T cells, 
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B cells, macrophages, and the expression of MHC class I [99]. The upregulation of MHC class 
І of muscle fibers is a characteristic histopathological feature of patients with myositis [100]. 
1.5.4 Adaptive immunity 
Adaptive immunity is the second line of the host defense, which is composed of highly 
specialized, systemic cells and that processes and eliminates pathogens or prevents their 
growth. Adaptive immunity creates immunological memory after an initial response to a 
specific pathogen and leads to an enhanced response to subsequent encounters with that 
specific pathogen. Unlike the innate immune system, the adaptive immune system is highly 
specific to a particular pathogen and can also provide long-lasting protection. 
1.5.4.1 Cell-mediated immunity 
Naïve CD8+ T cells and naïve CD4+ T cells are activated by recognizing antigens presented by 
APCs through MHC class І and MHC class ІІ molecules, respectively, in peripheral lymphoid 
organs. The full activation of both CD4+ T cells and CD8+ T cells requires two signals in the 
downstream signaling pathway. Signal 1 is the recognition between T cell receptor (TCR) on 
the surface of T cells and peptide presented by MHC class І or ІІ molecules. Signal 2 is the 
binding of CD28 expressed on the surface of T cells and CD80/CD86 (B7) expressed on the 
surface of APCs. CD28 plays an important role in decreasing the risk of T cell auto-immunity 
against host antigens. Without signal 2, T cells enter into a state without functional response 
named as anergy. The full activation of T cells could trigger the induction of downstream 
signaling pathways, which stimulates several transcription factors to regulate the proliferation 
and differentiation T cells and the production of different cytokines. CD4+ T cells differentiate 
into effector T cells (T helper cells, TH) with different subsets: TH1, TH2, TH17, T regulatory 
(Treg), and T follicular helper (TFH) cells. TH1 cells secrete IFN-γ, and activate phagocytes to 
clear up the ingested antigens, and induce the opsonization of complement proteins. TH2 cells 
activate eosinophils which secret IgE to combat mainly helminths by generating IL-4 and IL-
5. TH17 cells produce IL-17 which mainly help defend extracellular bacteria and fungi. Tregs 
inhibit the immune response and secret IL-10 and TGF-β. TFH cells help the activation of B 
cells in the germinal center of follicles of peripheral lymphoid node. CD8+ T cells differentiate 
into cytotoxic T cells which could kill the infected cells [101-103]. 
1.5.4.2 Immunological tolerance 
Theoretically, as the somatic recombination of genes of T and B cell receptors is random, there 
must be existing T and B cell receptors which recognize self-proteins or molecules (also called 
self-antigens). The cells interacting with self-antigens are called autoreactive cells. This process 
would lead to a cascade of autoimmune responses and attack of our own tissues or organs. 
However, this is not the case biologically. Our immune system has an ability to tolerate self-
antigens. The tolerance of self-antigens involves central tolerance and peripheral tolerance, 
depending on whether the tolerance occurs in central lymphoid organs (bone marrow and 
thymus) or in peripheral lymphoid organs (spleen and lymph nodes) [104]. 
Precursor T cells migrate from bone marrow to thymus and start further development. During 
the development, some T cells with high affinities undergo apoptosis (negative selection). But 
some other T cells with high affinities turn into Treg cells and go to the peripheral lymphoid 
organs to exert an immunosuppressive function. In peripheral lymphoid organs, the interaction 
of T cells with self-antigens lacks a strong co-stimulation, leading to apoptosis due to the lack 
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of ability to induce anti-apoptotic proteins or to anergy condition without functional response. 
Tregs inhibit the activation of autoreactive T cells by disturbing the costimulatory pathway and 
secreting inhibitory cytokines [104]. 
In central tolerance, B cells with weak interaction with self-antigens become functionally 
unresponsive. Upon very strong interaction, B cells either perform receptor editing or enter 
apoptosis. If the receptor editing fails, the B cells will go into apoptosis. In peripheral tolerance 
of B cells, the lack of help from T cells leads B cells into anergy or apoptosis. 
1.5.4.3 T cells – relationship with myositis 
T cells are present in muscle biopsies of all three major subgroups of myositis, but the subset 
and location of T cells differ between the subgroups [16]. In patients with DM, CD4+ T cells, 
are mainly distributed around capillaries in perivascular and perimysial area [16]. While in 
patients with PM and sIBM, the infiltrating inflammatory cells are located mainly in the 
endomysial area surrounding non-necrotic muscle fibers, and the predominating cells in the 
infiltrates are cytotoxic CD8+ T cells and CD4+ T cells [16]. The two patterns of infiltrating T 
cells indicate that T cells may affect different subsets of myositis via different pathways, one 
targeting the micro-vessels in muscle tissue and the second targeting the muscle fibers, but the 
immune specificity of the T cells is not known. The involvement of specific HLA-DR 
genotypes gives further support for a role of T cells in these disorders (HLA-DRB1*03:01 and 
DQA1*05:01), as a major role of the HLA molecules is to present antigens to T cells [105]. 
Thus, one discussed hypothesis is that the MHC class І expressing muscle fibers can serve as 
APCs to initiate the activation of cytotoxic CD8+ T cells. The cytotoxic CD8+ T cells could 
then lead to damage of non-necrotic muscle fibers via perforin pathways. In myositis, MHC 
class І molecules are up-regulated in muscle fibers, whereas MHC class І molecules are not 
expressed in healthy differentiated muscle fibers [6]. Although CD80 (B7-1) and CD86 (B7-
2) have not been detected on muscle fibers in myositis, BB-1, which is also a member of B7 
family of costimulatory molecules, has been detected in muscle fibers of patients with myositis 
[106]. Thus the MHC-class І/BB-1 positive muscle fibers may interact with cytotoxic CD8+ T 
cells with CD28 on their surface [6, 106]. This cascade has, however, not yet been fully 
elucidated. 
CD4+ T cells share similar steps to be activated as CD8+ T cells, except MHC class ІІ molecules 
are presenting the antigens instead of MHC class І molecules. After activation, CD4+ T cells 
could differentiate into T effector cells according to the microenvironment, such as TH1, TH2, 
TH17, and Treg cells. The four types of T effector cells have all been identified in patients with 
myositis, both in circulation and locally in the skeletal muscle [107-109], as suggested by the 
observation of locally expressed cytokines produced by different T cell phenotypes. 
The elevated expression of IFN-γ and IL-12 in the blood and muscle tissue of patients with 
myositis indicates the involvement TH1 cells in this condition [107, 110]. Growing evidence 
has shown that TH17 cells mediated pathway may also be involved and thus a potential target 
for therapy [109, 111]. Presence of elevated expression of IL-17 mRNA in muscle biopsies has 
been reported in the DM, PM, and IMB compared to controls [112, 113]. IL-22, a TH17 related 
cytokine, has been found overexpressed on protein level compared to healthy controls in 
muscle biopsies of DM/PM patients, and significantly correlated with disease activity of 
DM/PM [114]. TH1 and TH17 cell lines could indirectly mediate the regulation of muscle fibers 
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through different types of cytokines, and these cytokines could then regulate other 
inflammatory cells, thus, leading to a sequential autoimmune response [109, 115, 116]. 
TH2 related cytokines such as IL-4 and IL-13 have also been reported to be expressed in muscle 
tissue of myositis patients, especially in PM and sIBM patients [117]. The role of these 
cytokines in myositis is unclear. One possibility is that TH2-secreted cytokines could induce 
generation of M2 macrophages to repair the tissue. Another possibility is that TH2 cells could 
induce maturation and differentiation of B cells into autoantibody producing plasma cells 
[117]. 
FOXP3+ Treg is an important part of immunological tolerance by inhibiting the immune 
response. FOXP3+ Treg cells have been identified in muscle specimens of patients with DM, 
PM, and sIBM, and the expression of these cells correlates to the level of infiltration in muscle 
biopsies [118]. The number of FOXP3+ T cells was higher in muscle biopsies of patients with 
JDM compared to non-autoimmune disease controls, and the suppressive capacity of these 
Tregs was assumed defective [119]. No difference of the frequency of Tregs in circulation of 
JDM patients and healthy controls was observed, while in adult patients with DM the number 
of Tregs was significantly reduced compared to healthy controls [119, 120]. The data imply 
that different pathogenic mechanisms may predominate in children and adults with DM. 
FOXP3+ T regulatory cells could not only inhibit the function of CD4+ T cells and CD8+ T 
cells, but also suppress the maturation and antigen-presenting function of DCs [118, 121]. 
Thus, Tregs may play a pivotal role in human myositis. This is also supported by the data 
showing that specific muscle antigen like myosin could develop a spontaneous myositis in 
FOXP3 mutant mice [122]. Furthermore, one study showed that injection of polyclonal Tregs 
could decrease the severity of myositis in a mouse model of autoimmune myositis [123]. The 
Treg cells is a key regulator in the autoimmune disease, which definitely makes Treg an 
interesting target for immune therapy in patients with myositis.  
Further phenotyping of CD4+ and CD8+ T cells have revealed a predominance of CD28null T 
cells of both CD4 and CD8 phenotypes in muscle tissue and peripheral blood of myositis 
patients [9, 124]. CD28 null T cells constitute a subset of T cells with cytotoxic properties lacking 
the expression of the costimulatory molecule CD28. This subset of T cells is regarded as a 
marker of senescence of the immune system and is usually present in elderly healthy 
individuals and in patients with chronic inflammatory conditions [125-127]. CD28 null  T cells 
express some receptors, which are absent in conventional CD28+ T cells, such as OX40/4-1BB 
costimulatory receptors, activating NK cell receptors (NKG2D), and CX3CR1 (fractalkine 
receptor) [128]. These receptors may help the proliferation of CD28null T cells compensating 
the lack of CD28 and exert the cytotoxic function of CD28null T cells. 
These pro-inflammatory and terminally differentiated CD28null T cells are resistant to apoptosis 
and they are long-time living. These features may contribute to treatment resistance in myositis 
patients [9]. Compared to CD28+ T cells, CD28null T cells mainly secret IFN-γ and TNF-α [9, 
128], and these molecule could promote the expression MHC class І and MHC class ІІ on 
muscle fibers of DM and PM patients, which could give rise to the sequential immune response 
as mentioned earlier. Another distinct feature of CD4+CD28null T cells is the secretion of 
perforin and granzyme, a mechanism via which CD4+CD28null T cells gain cytotoxic function 
that may directly damage the muscle fibers of myositis patients [9, 128]. In fact, CD4+CD28null 
T cells and CD8+CD28null T cells are frequently found in muscle specimens of DM and PM 
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patients, and functional in vitro studies have demonstrated a myocytotoxic capacity of these T 
cells [9]. 
Several cytokines are important for the CD28null T cell activity. For example, IL-15 is an 
important cytokine, which could not only promote the generation and proliferation, but also 
enhance the cytotoxic properties of CD28null T cells [129, 130]. This has been proven in 
different disease conditions [131-133]. In contrast, IL-12 may induce the expression of CD28 
and could restore the costimulatory activity of CD4+CD28 null T cells [134]. Without CD28 
expression, CD28null T cells cannot initiate proliferation through the classical stimulation 
pathway CD28/B7. CD58/CD2 was reported as a primarily replaced costimulatory pathway in 
human CD8+CD28null T cells in vitro [135]. After treatment with glucocorticoids a higher 
frequency of CD28null T cells was found in muscle tissue of patients with myositis, compared 
to the reduced frequency of Tregs [136]. 
1.5.4.4 Humoral immunity 
Naïve B cells in follicles of lymph node are activated by invading pathogens or antigens 
presented by follicular dendritic cells, and then migrate into the T cell zones from lymphoid 
follicles. After the processing of the pathogens or antigens, activated B cells present the 
processed peptides to helper T cells in the parafollicle areas, which have been stimulated by 
the same antigens presented by dendritic cells. The interaction between T helper cells and B 
cells may induce the proliferation and differentiation of some B cells, which will only express 
limited isotypes of antibodies (mainly IgD and IgM) and become short-lived plasma cells. 
Some other activated B cells and T helper cells will migrate back to lymphoid follicles, where 
B cells are further activated by T helper cells (specifically named TFH cells). Further activated 
B cells migrate into the germinal center, where they undergo somatic hyper-mutation and heavy 
chain class switching and proliferate and differentiate into plasma cells and memory B cells. 
Hyper-mutation cause mutations within the genes to increase affinity, diversity, and specificity 
of antibodies, and heavy chain class switching could change the isotypes of the antibodies due 
to different antigens involved [137, 138].  
There are four different isotypes of antibodies circulating in blood secreted by plasma cells. 
IgG is the main antibody in circulation, with the function of opsonizing antigens to help 
phagocytosis, neutralizing microbes and toxins, activating classical complement pathway, and 
crossing placenta and gut. IgM is the first produced antibody when exposed to invading 
pathogens and is present as a pentamer structure in blood, helping the activation of classical 
complement system. IgA is secreted as a monomer or a dimer structure, mainly distributed in 
mucosal sites to defend against invading pathogens. IgE could bridge antigens and mast cells 
and simulate mast cells to secrete histamine, which is important in mediating hypersensitivity 
reactions. IgE are involved in the defense against parasites and worms. IgD is expressed on the 
membrane of B cells instead of plasma cells, which is a marker of mature B cells [138]. 
1.5.4.5 B cells and autoantibodies – relationship with myositis 
B cells and plasma cells can be detected in muscle tissue of patients with DM, PM, and sIBM 
[139]. The successful application of rituximab, a B cell-blocking therapy, supports the 
contribution of B cells in the immune mechanism of myositis [28]. Furthermore, the presence 
of circulating autoantibodies also supports the involvement of B cells in the pathogenesis of 
myositis, at least in the subgroups with autoantibodies. Autoantibodies in patients with myositis 
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are separated into two categories with the generally clinical consent [140]: MSAs, which are 
specific for myositis patients, and MAAs, also present in other connective tissue diseases. 
The MSAs include the classical autoantibodies targeting the following autoantigens [140]: 
aminoacyl tRNA synthetases (ARS), nucleosome remodeling deacetylase complex (NuRD), 
signal recognition particle (SRP), as well as several lately found autoantigens: transcription 
intermediary factor 1γ/α (TIF1γ/α, p155/140), melanoma differentiation-associated protein 5 
(MDA5), nuclear matrix protein 2 (NXP-2), small ubiquitin-like modifier-1 (SUMO-1) 
activating enzyme (SAE), and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). 
These autoantibodies support diagnosis of myositis, help predict the clinical manifestations, 
and also seem to be able to predict the prognosis of the disease although cohort studies with 
long term follow up are scarce and more studies are needed [12, 141]. A list of MSAs is 
presented in Table 3. 
 
Table 3. Myositis-specific autoantibodies and typical extramuscular clinical symptoms. 
Autoantibody Target antigen Associated symptoms Associated subset of 
myositis 
Anti-ARS Aminoacyl t-RNA 
synthetases 
ILD [11], arthritis, 
Raynaud´s 
phenomenon, 
mechanic´s hands 
ASS [142] 
Anti-Mi-2 Nucleosome remodeling 
deacetylase complex 
Skin rash [12] DM [12] 
Anti-SRP Single recognition 
particle 
Dysphagia, high CK 
[143] 
 
IMNM [143] 
Anti-TIFΙγ (p155) Transcription 
intermediary factor 1γ 
Skin rash, cancer 
[144] 
DM [144] 
JDM 
Anti-MDA-5 Melanoma 
differentiation 
associated protein 5  
ILD, Rapidly 
progressive ILD, skin 
rash [145, 146]   
DM, CADM [145, 
146] 
Anti-MJ/NXP2 Nuclear matrix protein 2 Heliotrope rash, 
calcinosis, cancer 
[147, 148]  
DM [147, 148], JDM 
Anti-SAE Small ubiquitin-like 
modifier activating 
enzyme 
Skin rash, dysphagia 
[149, 150] 
DM [149, 150] 
Anti-HMGCR 3-hydroxy-3-
methylglutaryl-
coenzyme (CoA) 
reductase 
Muscle deficit, high 
CK [151] 
IMNM [151] 
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Anti-FHL1 Four-and-a-half LIM 
domain 1 
Severe myopathy, 
often treatment 
resistant 
DM, PM, and sIBM 
Anti-cN-1A Cytosolic 5′-
nucleotidase 1A 
Muscle weakness and 
atrophy 
sIBM 
ILD: interstitial lung disease; CK: creatine kinase; ASS: anti-synthetase syndrome, IMNM: 
immune mediated necrotizing myopathy; CADM: clinically amyopathic dermatomyositis 
 
1.5.4.5.1 Anti-ARS antibodies 
Anti-ARS antibodies target a family of proteins termed as cytoplasmic aminoacyl tRNA 
synthetases. To date, autoantibodies against 8 of these ARS have been described in myositis: 
anti-hystidyl (Jo-1), anti-threonyl (PL-7), anti-alanyl (PL-12), anti-glycyl (EJ), anti-isoleucyl 
(OJ), anti-asparaginyl (KS), anti-phenylalanyl (ZO), and anti-tyrosyl (YRS/HA) antibodies. 
Anti-Jo-1 antibodies targeting histidyl-transfer RNA synthetase (HisRS) are more frequent 
than other anti-ARS antibodies, being present in up to 20-30% of patients with myositis [140, 
152]. 
Anti-synthetase syndrome is a clinically specific subset of myositis, with symptoms of ILD, 
myositis, fever, polyarthritis, Raynaud’s phenomenon, and mechanic’s hands, and is associated 
by presence of the anti-ARS antibodies [142]. Of the symptoms generally present, ILD is 
common and is a leading cause of death among these patients [11]. Of note, anti-Jo-1 antibodies 
showed an association with ILD in myositis patients and also correlated to the disease activity 
of myositis patients [141], showing that anti-Jo-1 antibody is a promising biomarker to predict 
the presence of ILD and also the disease activity of these patients. Sera with anti-Jo-1 
antibodies could induce type І IFN signaling pathway, and also stimulate the overexpression 
of intercellular adhesion molecule-1 (ICAM-1) in human lung endothelial cells, indicating their 
involvement in the pathogenesis of myositis disorders [95, 153].  
1.5.4.5.2 Anti-Mi-2 antibodies 
Anti-Mi-2 antibodies target a particular region of a complex protein, nucleosome remodeling-
deacetylase (NuRD). The main function of NuRD is to modify the generation of chromatin 
[154]. Anti-Mi-2 antibodies are associated with typical skin rash of DM and usually are 
associated with good prognosis [12, 154]. 
1.5.4.5.3 Anti-SRP antibodies 
The SRP antigen is a conserved cytoplasmic complex with six ribonucleoproteins and one 7S 
RNA, and the function of SRP is to recognize secretory proteins and regulate their translocation 
across the rough endoplasmic reticulum (ER) [155]. Anti-SRP antibodies are mainly detected 
in patients with IMNM, with the histological features of necrotizing fibers and few infiltrates 
in muscle biopsies [143]. Patients with anti-SRP antibodies often have pronounced muscle 
weakness and they respond poorly to conventional immunosuppressive treatment.  
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1.5.4.5.4 Other autoantibodies 
Besides the above described autoantibodies, several new autoantibodies specific for myositis 
have also been identified. Anti-TIFІγ (p155) antibodies are associated with DM patients, 
especially DM patients with cancer, as well as with JDM patients [144]. MDA5 is a receptor 
that recognizes viral double-stranded RNA (dsRNA) in cytoplasm [156]. CADM is a subset of 
myositis with the typical cutaneous manifestations of DM patients, but no muscle symptoms 
involvement [5]. Anti-MDA5 antibody is a predictive biomarker of CADM, which is also 
associated with a rapidly progressive ILD [145, 146]. Anti-MJ/NXP2 antibodies mainly exist 
in DM patients and in patients with JDM, and are rarely found in PM patients. These 
autoantibodies are associated with clinical features of calcinosis and cancer, however, the 
clinical manifestations are not consistent across patients from different ethnical source [147, 
148]. Anti-TIFІγ and anti-NXP-2 antibodies are both associated with DM and cancer, but not 
all patients with these antibodies develop cancer and not all patients with DM and cancer have 
any of these autoantibodies [144, 157]. The antigen SAE is a group of enzymes associated with 
post-translational processing known as protein sumoylation. The anti-SAE antibodies are 
primarily present in DM patients with frequent skin lesions, systemic symptoms, and dysphagia 
[149, 150]. Anti-HMGCR antibodies are mainly detected in patients with immune mediated 
necrotizing myopathy [151]. Anti-four-and-a-half LIM domain 1 (FHL1) antibody is a muscle 
specific autoantibody, identified in patients with DM, PM, and sIBM. Myositis patients with 
anti-FHL1 antibodies often have a severe muscle pathology and are treatment resistant [158]. 
Another muscle-specific autoantibody against cytosolic 5′-nucleotidase 1A (cN-1A) is specific 
for sIBM, which may be a potentially diagnostic marker of sIBM [159]. 
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2 AIMS OF THE STUDY 
The overall objective of this study was to increase the knowledge about the immune 
mechanisms involved in myositis from innate and adaptive immune angels. The specific aims 
of each project are as follows: 
 
Project 1. To evaluate the effects of abatacept on disease activity and the target organ, skeletal 
muscle, of adult patients with dermatomyositis (DM) and polymyositis (PM) (ARTEMIS 
trial).  
 
Project 2. To evaluate in vivo effects of abatacept on phenotypes of T and B cells in the 
circulation and in muscle tissue in available samples from the ARTEMIS trial using mass 
cytometry (CyTOF). 
 
Project 3. To explore a potential role of LL-37 in relation to the type І interferon system in 
patients with dermatomyositis (DM) and polymyositis (PM).  
 
Project 4. To identify biomarkers in paired muscle biopsies and blood samples, taken before 
and after conventional immunosuppressive therapy, which could predict therapeutic response 
in myositis patients. 
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3 PATIENTS 
3.1 PATIENTS IN PROJECT 1 
Twenty adult patients (13 females and 7 males) with a median age of 51.5 years (range: 45.3-
58.8 years) from Karolinska University Hospital, Stockholm, Sweden; King’s College Hospital 
NHS, London, UK; and the Institute of Rheumatology Prague, Prague, Czech Republic were 
included in this study. The patients were diagnosed with DM (n=9) and PM (n=11) according 
to Bohan and Peter criteria [18, 19]. The patients had active disease after 3 months of 
conventional treatment with a combination of glucocorticoids and immunosuppressive agents. 
Repeated muscle biopsies were available from six patients from Sweden.  
Muscle biopsies were investigated by immunohistochemistry staining for different markers 
(CD3, CD4, CD8, Ki67, CD68, CD163, CD19, CD19+CD20 (Clone no: L27), CD20cy (Clone 
no: L26), CD244, CTLA-4, DC-LAMP-PE, FOXP3, CD31, TNF-α, and IL-15). 
3.2 PATIENTS IN PROJECT 2 
Project 2 is a sub-study of project 1. Therefore treatment, inclusion criteria, and exclusion 
criteria are the same as in project 1. 
Twelve patients with repeated peripheral blood mononuclear cells (PBMCs) taken before and 
after 6-months of abatacept treatment were included in Project 2. The patients (8 females and 
4 males, 6 DM and 6 PM) were form Karolinska University Hospital, Stockholm, Sweden and 
Institute of Rheumatology Prague, Prague, Czech Republic. Five of the twelve patients had 
paired muscle biopsies. Conclusive summary of patients in Project 1 and Project 2 are presented 
in Figure 2. 
PBMCs were investigated focusing on T and B cell phenotypes by CyTOF with a panel of 29 
antibodies, respectively. Muscle biopsies from Project 1 were investigated by 
immunohistochemistry including staining for CD3, CD4, CD8, FOXP3, CD244, CD19, 
CD19+CD20 (Clone no: L27), and CD20cy (Clone no: L26). Expressions of CD3, CD4, and 
CD8 from Project 1 were re-evaluated in Project 2. In Project 1, CD3, CD4, and CD8 
expressions were quantified by the percentage of positively stained areas of the whole section 
area, whereas in project 2, calculation of the number of positively stained cells per total tissue 
area (mm2) was used. 
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Figure 2. Diagram of patients distributed in Project 1 and Project 2. ITT: intention-to-treat 
population, meaning all patients randomized and given at least one baseline and following 
efficacy evaluation after treatment. PP: per protocol population, meaning all patients in the ITT 
population who also continued until week 24 without any violations according to the trial 
design. SAE: serious adverse event. 
 
3.3 PATIENTS IN PROJECT 3 
Patients in Project 3 include patients with myositis and SLE, and healthy controls. 
Twelve patients (6 females, 6 males) with a mean age of 57 years (range: 40-77 years) were 
diagnosed with DM (n=6, 4 definite and 2 probable) and PM (n=6, 4 definite and 2 probable) 
by Bohan and Peter criteria [18, 19]. Eight of the twelve patients with short disease duration 
(symptoms ≤ 6 months, median 3 months, range: 1-6 months) were not treated except one 
patient who was given treatment 4 months before the muscle biopsy was taken. The other four 
patients with long disease duration (median 120 months, range: 60-216 months) were treatment 
resistant. Six SLE patients and eleven healthy subjects were enrolled as positive and negative 
controls, respectively. The median age of the six female SLE patients was 62 years (range: 37-
77 years). Muscle biopsies were taken from five healthy controls with a median age of 58 years 
(range: 36-69 years). Skin biopsies were collected from another six healthy controls with a 
median age of 43 years (range: 32-51 years). The gender of the healthy controls was not known. 
Muscle biopsies and skin biopsies from patients and controls were analyzed by 
immunohistochemistry staining for LL-37, CD66b, MxA, BDCA-2, CD68, CD163, and CD31. 
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Serum samples were evaluated for 25(OH)D3 by chemiluminescence immunoassay technique. 
The patients and healthy controls and corresponding samples are presented in Figure 3. 
 
Figure 3. Diagram of the patients, muscle biopsies, and skin biopsies involved in Project 3. 
SLE: systemic lupus erythematosus; DLE: discoid lupus erythematosus; SCLE: subacute 
cutaneous lupus erythematosus.  
 
3.4 PATIENTS IN PROJECT 4 
Thirteen patients (8 females and 5 males) with myositis were enrolled in this project with the 
following diagnosis: DM (definite n=4), PM (definite n=4, probable n=3), IBM (definite n=2) 
based on the 2017 EULAR/ACR classification criteria [22, 23]. The median age at time of 
diagnosis was 65 years (range: 45-84 years). Clinical information was collected at time of 
diagnosis (pre-treatment), at 1- and 3-year follow-up. Selection of treatment was based on 
decision of the treating physician and consisted of a combination of glucocorticoids and 
immunosuppressive agents. Muscle biopsies and PBMCs were collected at time of diagnosis 
and within 1-year of follow-up (Figure 4). 
Muscle biopsies were evaluated by immunohistochemistry including staining for markers of 
CD3, CD68, CD163, IL-15, MHC class І, and MHCn. Blood samples were analyzed by flow-
cytometry for monocytes and T cells. 
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Figure 4. Diagram of the patients, muscle biopsies, and blood samples involved in Project 4. 
MHCn: myosin heavy chain neonatal. 
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4 METHODS 
The following methods were used for the 4 projects. 
4.1 MUSCLE BIOPSIES 
4.1.1 Muscle biopsy technique 
The morphological evaluation of muscle biopsies is an important tool to diagnose myositis. 
Immunohistochemistry staining of different molecular makers in muscle biopsies could not 
only provide more information for diagnosis but could also serve as an important tool to explore 
the underlying pathological mechanisms. 
The general method for muscle biopsies used in Sweden is the “semi-open” muscle biopsy 
technique [160]. After local anesthesia, an alligator forceps (Weil-Blakesley´s conchotome) 
was used to take muscle biopsies by an experienced rheumatologist from various muscles like 
vastus lateral or tibialis anterior muscle. It is possible to take multiple muscle biopsies in the 
same site. This method is easily performed and gives enough material for clinical diagnosis 
and research purpose without causing much uncomfortable feelings or large scars. When 
repeated muscle biopsies are taken, changes in morphology and molecular expression of 
muscle biopsies can be investigated at different time-points in the disease course. 
4.1.2 Handling of muscle biopsies 
A good quality of muscle biopsies is the foundation for the morphological evaluation and 
immunohistochemistry staining. Muscle biopsies are very sensitive and therefore they need to 
be frozen properly to prevent artifacts and morphology destruction.  
Different freezing methods were used for different research purposes. Muscle biopsies for PCR 
were frozen in isopentane pre-chilled by liquid nitrogen within seconds when taken from 
patients. While the muscle biopsies for immunohistochemistry were put on a moist sterile tissue 
in a plastic box on ice for 15 minutes before putting into pre-chilled isopentane. The frozen 
biopsies were then put in sterile pre-chilled tubes, containing a small piece of sterile ice in order 
to protect the samples from freeze drying during storage. The tubes were kept on dry ice until 
stored for longer time in -80 ℃. 
4.1.3 Sectioning of muscle biopsies 
The muscle biopsies were kept on dry ice when taken from -80 ℃. The muscle biopsies were 
put on a pre-cooled metal specimen holder in the cross-section direction and then mounted by 
OCT Cryomount medium (45830, HistoLAb, Gothenburg, Sweden). Then both the holder and 
the muscle biopsy were quickly dipped into liquid nitrogen until the OCT became frozen. 
Mounted muscle biopsies were sectioned into 7-um-thick specimens by using the Cryostat 
(CRYOSTAR NX70, Thermo Scientific, US). The cut muscle specimens were put on chrome-
gelatine coated slides (Thermo Scientific, US), and air dried at room temperature for 30 
minutes. To track the histology of continuous sections, Mayer´s HTX and eosin were used to 
stain the first and last section. 
The slides were then fixed according to the features of different molecular markers to be 
stained. For intracellular antigen staining, slides were fixed by 4 ℃ 2% formaldehyde for 20 
minutes and then washed twice in 4 ℃ 1xPBS for 5 minutes respectively before storage in -80 
 30 
℃. For cell surface antigens, the slides were fixed in 4 ℃ 50% acetone for 3 minutes and then 
4 ℃ 100% acetone for 30 seconds before storage in -80 ℃. 
4.2 SKIN BIOPSIES 
Skin biopsies were taken by a punch method [161] under local anesthesia by an experienced 
dermatologist or rheumatologist. The handling, freezing, and sectioning of skin biopsies were 
similar to muscle biopsies. 
4.3 IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE STAINING 
Immunohistochemistry staining is a technique to investigate molecular expressions at protein 
level in target organs such as muscle and skin and provides information of cellular localization 
of the investigated molecule. Saponin is a cholesterol-like detergent, which permeabilizes cell 
surface membrane allowing the access of antibodies into cytoplasm. Thus, saponin is essential 
for intracellular staining. As the permeabilization is reversible, saponin has to be present in all 
steps during the whole staining process.  
In our lab, avidin-biotin-peroxidase complex (ABC) method is used for immunohistochemistry 
staining. Avidin has four sites that binds biotin with high affinity. When the primary antibody 
recognizes antigens in the tissue it will bind to the biotinylated secondary antibody. Open sites 
of avidin then binds to biotin on the secondary antibody which is labelled with horseradish 
peroxidase (HRP). The substrate (DAB) is catalyzed by HRP and develop color.  
To block endogenous peroxidase activity 1% H2O2 was often used before adding the primary 
antibody. Serum which the secondary antibody was produced in was used to block the non-
specific binding of antibodies to tissue or to Fc receptors. After application of the secondary 
antibody, the sections were treated with ABC Elite kit (PK-6100, Vector Laboratories, 
Burlingame, CA, USA). Then peroxidase substrate kit containing 3, 3’-diaminobenzidine 
(DAB) (SK-4100, Vector Laboratories, Burlingame, CA, USA) was added to the sections for 
color reactions. Mayor’s hematoxylin was used to stain the nuclei of cells. Finally, the slides 
were mounted with glycerol and investigated under optical microscope. 
Before performing the staining of patients’ materials, choosing proper primary antibodies, 
titration of primary antibodies, and test of optimal protocol are essential for a successful 
staining. Higher concentration of serum, different origins of serum blocking, and biotin-avidin 
blocking steps are recommended based on the basic staining protocol considering the 
nonspecific staining as background. Negative controls and positive controls are essential to 
confirm the specific staining of the target antigens. 
Immunofluorescence staining was used in two of my studies to confirm the co-localization of 
two different molecular markers. The staining procedures are similar as for 
immunohistochemistry staining except that a fluorophore is used as a color signal instead of 
DAB. Of note, the two primary antibodies should be from different species to avoid any cross 
reaction. The staining should be performed in darkness after application of fluorophore. 4’, 6-
diamidino-2-phenylindole (DAPI) (Roche, Stockholm, Sweden) for cell nuclei. 
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4.4 PEPTIDE BLOCKING 
A mixture of blocking peptide and primary antibody (in appropriate proportions) was prepared 
and kept in 4 ℃ one day before the staining procedure. The day of the staining, saponin was 
added to a final concentration of 0.1% (the same concentration as for the other 
immunohistochemistry staining). The staining procedures were then the same as for the 
immunohistochemistry staining. 
4.5 QUANTIFICATION 
We used a Reichert Polyvar II microscope (Reichert-Jung, Vienna, Austria) and a digital Leica 
camera DFC450 C (Leica, Cambridge, UK) to investigate the staining, visualize the 
morphology, take pictures, and manually count cells. A Leica DMRXA2 (Leica, Cambridge, 
UK) and Leica digital camera DFC450 C (Leica, Cambridge, UK) were used to take pictures 
of fluorescence staining and to perform computerized image analysis.  
The Leica TCS SP5 Confocal (Leica Microsystems, Cambridge, UK) was used to take pictures 
of fluorescence staining. 
Although the immunohistochemistry staining is a descriptive method, quantification can still 
be performed by using computerized image analysis system. This method could partially 
reduce the subjective bias of human eyes, but the computer cannot adjust the color threshold 
of positivity according to the different staining intensity in different sections, which has to be 
set manually to make the evaluation more consistent in different samples. The sections can also 
be scored by manual counting of number of positively stained cells in relation to the total tissue 
area calculated by computerized image analysis and presented as a grading score. 
The estimation of expression of a stained molecule by image analysis can be performed in 
different ways according to the different expression patterns of molecular markers stained. If 
the molecular markers were positive in large areas of most samples, the percentage of positively 
stained areas of the whole section area was used. While if only scattered positive cells are 
detected, calculation of positively stained cells per total tissue area (mm2) was a better 
alternative.  
4.6 ISOLATION OF PBMCS 
The heparinized blood samples were diluted in PBS buffer. Ficoll-Paque medium were 
carefully added to the bottom of the blood tube. The tubes were centrifuged at room 
temperature at 1660 rpm for 20 minutes. The PBMCs (located between the top plasma layer 
and the ficoll medium) were transferred to a new tube. The PBMCs were then washed with 
PBS and centrifuged at 1660 rpm for 7 minutes. The supernatant was then removed. The 
washing procedure was repeated three times. The PBMCs were counted and freezing medium 
(90% fetal bovine serum (FBS) in combination with 10% of dimethyl sulfoxide (DMSO)) were 
then added before freezing. The PBMCs were kept at -80 ℃ until use. 
4.7 CYTOF 
Mass cytometry, also named Time of Flight Mass Cytometry (CyTOF), is a combination of 
flow cytometry and mass spectrometry in which cells are stained with antibodies labeled with 
heavy metal ion rather than fluorochrome, allowing for up to 40-simultaneous antibodies to be 
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quantified in individual cells at a rate of about 500-1000 cells/second without the overlap of 
emission spectra [162]. 
CyTOF gives large amounts of data which could be a challenge to analyze. T-Distributed 
Stochastic Neighbor Embedding (t-SNE) map, spanning-tree progression analysis of density-
normalized events (SPADE), cluster identification, characterization, and regression (Citrus) are 
commonly methods to analyze the CyTOF results. T-SNE map was exported by PhenoGraph 
[163], displaying multi-dimensional data on a two dimensional dot plot, and the location of 
each dot is the projection of the relationship of each cell in the high-dimension space [164]. 
SPADE is a tool to reduce the multidimensional data into two dimensions on a minimum 
spanning tree (MST) formed by cell clusters based on the similarities of surface phenotypes 
[165]. Citrus is used to identify clusters that predict the differences between different end points 
by using a hierarchical algorithm and a prediction model [166]. One disadvantage of CyTOF 
is that the cells are destroyed during the running, so it is important to reserve the same samples 
for necessary downstream experiments. As CyTOF is a new method, it is necessary to confirm 
the results of CyTOF by using other generally accepted methods, like flow cytometry.  
4.8 FACS 
Fluorescence activated cell sorting (FACS) of live cells could separate a group of cells 
recognized by antibodies labeled by fluorescence into sub-groups. Frozen PBMCs were 
thawed, filtered by Falcon 40 µm cell strainer, and counted by Scepter™ automated cell 
counter (Millipore, Germany). Single cell suspensions (one million cells per sample) were 
plated in 96-well V-bottom plate and stained with the antibodies. LIVE/DEAD Fixable Dead 
Cell Stain Kit (Invitrogen) was applied to exclude dead cells. Gallios flow cytometer (Beckman 
Coulter, Brea, CA) and Kaluza v1.1 software (Beckman Coulter) were used to analyze the 
samples. 
4.9 STATISTICS 
Statistical analyses were performed by GraphPad Prism 6 (San Diego, Calfornia, USA). 
Fisher’s exact test was used to test for significance of association between the two kinds of 
variables. Mann-Whitney U test was used for the comparisons between two independent 
groups with nonparametric distribution data. Student’s t-test was used to compare two groups 
of parametrically distributed data. Nonparametric Wilcoxon matched-pairs signed rank test 
was applied to compare two paired groups. Friedman test was used to calculate the differences 
among three groups with paired samples, followed by a Dunn’s post-test to correct for multiple 
comparisons. Kruskal-Wallis test was used to calculate the differences of three groups with 
unpaired samples. Nonparametric spearman`s Rank correlation was applied to calculate the 
correlation between two variables. Pearson correlation was used to calculate the correlation 
between two variables normally distributed. P<0.05 was considered significantly different.  
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5 RESULTS AND DISCUSSION 
Myositis is a group of heterogeneous and rare autoimmune disease with the target tissue of 
skeletal muscle. It is not curable and affects the daily life of patients. The treatment of myositis 
is mainly glucocorticoids in combination with immunosuppressive agents. If the patients do 
not respond, within 3-6 months the physicians generally change to alternative treatment. The 
incomplete response and common side effects of conventional immunosuppressive treatment 
requires new therapies. The molecular mechanisms of myositis are still not known, which is 
the primary limitation to the discovery of new and effective treatments.  
5.1 ABATACEPT IN THE TREATMENT OF ADULT DERMATOMYOSITIS AND 
POLYMYOSITIS (ARTEMIS) 
        (Project 1 and Project 2)  
5.1.1 Delayed-start design 
As this was a new treatment in patients with myositis, an open label trial was planned. 
However, to strengthen the power of the trial, we used a randomized delayed-start design [167] 
(Figure 5). The patients were randomized into Arm A (active group, n=11) and Arm B (delayed 
group, n=9). Patients in the active group were given abatacept treatment from the first visit, 
while patients in the delayed-start group were treated with abatacept after 3 months delay. All 
the patients were given 6 months of active abatacept treatment. 
After 3 months from the start of the trial (patients in Arm A with abatacept treatment for 3 
months, whereas patients in Arm B with no abatacept treatment) there were more responders 
(n=5) in Arm A compared to Arm B (n=1) (Table 4).  
Three months delay was chosen because it was hypothesized to be sufficient to observe effects 
of abatacept treatment on disease symptoms, furthermore, a longer delay would be unethical 
for the non-treated patients. Even though both groups were treated by abatacept, without a 
placebo group, we could still compare patients treated with abatacept for 3 months to patients 
without abatacept treatment. As more patients were improved after 3 months of abatacept 
treatment than patients without abatacept treatment this may suggest that the response was due 
to the beneficial effects of the short time treatment of abatacept or individual differences, rather 
than by modification of the disease itself.  
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Figure 5. The design of the trial to investigate the effect of abatacept on DM and PM. The 
patients were randomized into two groups: Arm A and Arm B. The patients in Arm A were 
given abatacept treatment from the first visit, while patients in Arm B were treated after 3 
months delay. All the patients were given 6 months of active abatacept treatment. W: week. 
Screening period is to ensure no malignancy and for wash out period of prohibited therapies. 
 
Table 4. Response to abatacept treatment in different time points. 
Response after 3 months from start 
n=19 Responders (n=6) Non-responders (n=13) 
Arm A (n=10) 5  5  
Arm B (n=9) 1 8  
Response after 6 months from start 
 Responders (n=7) Non-responders (n=12) 
Arm A (n=10) 6 4 
Arm B (n=9) 1 8 
Response after 6 months of active treatment 
 Responders (n=8) Non-responders (n=11) 
Arm A (n=10) 6 4 
Arm B (n=9) 2 7 
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5.1.2 Clinical effect of abatacept treatment on patients with DM and PM 
After 6 months from the start of the trial (patients in Arm A with abatacept treatment for 6 
months, while patients in Arm B with abatacept treatment for 3 months), one more patient 
became responder than after 3 months in Arm A (n=6 vs n=5), whereas no difference was 
registered in the number of responders in Arm B (n=1). Within arm B there was one more 
responder after 6 months of abatacept treatment (n=2) in comparison to after 3 months of 
abatacept treatment (n=1) (Table 4). In general, there were more responders in Arm A than 
Arm B after both three months (n=5 vs n=1) and six months of active abatacept treatment (n=6 
vs n=2) (Table 4).  
Most patients responded to abatacept after 3 months, while a small group of patients showed 
response only after 6 months of abatacept treatment in both Arm A and Arm B. In line, in a 6-
month trial to investigate the effect of abatacept in RA patients, more improvement of disease 
activity was also observed after 6 months than 3 months of treatment, however, without 
reaching a significant difference [168]. It seems likely that 3 months was sufficient for the 
beneficial effect of active abatacept treatment for the majority of patients, but 6 months of 
active abatacept treatment was required for a minority of patients to improve. More responders 
were defined in Arm A than Arm B after both three and six months of active abatacept 
treatment. The reasons are not known. However, the difference observed between Arm A and 
Arm B is the 3 months delay and the median age at baseline of Arm A was higher than Arm B 
(P<0.05), which may be the reasons leading to more responders in Arm A than Arm B after 6 
months of active abatacept treatment.  
In total (both Arm A and Arm B), nineteen patients were included in the analysis of the results. 
According to the definition of improvement by IMACS criteria [24], 8 patients were responsive 
to the treatment and 11 patients were not. During the treatment of DM and PM patients, eight 
of thirty-six adverse events reported were associated with the administration of abatacept, with 
four mild and four moderate, whereas no severe side events were registered. The most common 
adverse event was infections.  
Most DM and PM patients do not completely respond to conventional therapy of 
gluococorticoid and immunosuppressive agents, furthermore, unwanted side effects often 
follow. Abatacept has shown efficacy and well tolerance in patients with rheumatoid arthritis 
and psoriatic arthritis [32, 169]. After 6 months of abatacept treatment, almost half of the 
enrolled patients who previously had not responded to conventional immunosuppressive 
treatment showed response to the treatment according to the IMACS definition of improvement 
[24] and no severe adverse events were related to abatacept treatment. 
5.1.3 Effect of abatacept treatment on muscle performance of patients with 
DM and PM 
The muscle strength presented by MMT-8 significantly improved (P<0.05) and the muscle 
disease activity also significantly decreased after 6 months of active abatacept treatment 
(P<0.05) for patients in both Arm A and Arm B. The MMT-8 of six patients with repeated 
muscle biopsies also showed a numerical increase (median (IQR) 72.00 (60.25-74.00) -73.50 
(66.00-78.50)) after abatacept treatment. There was also a numerical improvement in all the 
variables of functional index (FI)-2 representing the muscle endurance of patients with 
myositis, especially right shoulder flexion (P<0.05) and heel lift (P<0.05) with significant 
improvement. 
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Muscle weakness is a characteristic clinical manifestation for most DM and PM patients, 
causing negative effect on the daily activities and the quality of life. After 6 months of abatacept 
treatment, the muscle performance of DM and PM patients improved significantly. Some other 
biological therapies have shown efficacy with lower disease activity in DM and PM patients in 
clinical trials, but no biological treatment has shown significant improvement of muscle 
performance to date. This makes abatacept a promising biological drug to directly relieve 
muscle weakness of treatment resistant DM and PM patients.  
5.1.4 Effect of abatacept treatment on expression of molecular markers in 
muscle biopsies 
The number of FOXP3+ Tregs in muscle tissue significantly increased after 6 months of 
abatacept treatment although the muscle biopsies were only available for six patients. However, 
no significant differences were noted for any other marker which we stained for. This may be 
due to the different co-stimulation requirements between regulatory T cells and effector T cells, 
as abatacept is a modulator of CD28/B7 co-stimulation [170]. 
FOXP3+ Treg cells mediate the tolerance of immune system by suppressing immune reaction. 
FOXP3+ Tregs have been observed close to the effector cells in muscle tissue of DM and PM 
patients [109]. The number of FOXP3+ Tregs was significantly higher in muscle of JDM 
patients comparing to controls, but the capacity to suppress inflammation of these Tregs in 
muscle was assumed defective due to the high number of FOXP3+ Tregs with high level of 
inflammation. In addition, in the in vitro co-culture system of blood derived-Tregs and T 
effector cells, the suppressive ability of Tregs from active JDM patients was also lower than 
the cells from JDM patients in remission [110]. However, in RA patients, the suppressive 
ability of Tregs in synovium treated with abatacept was not affected [171]. The number of 
FOXP3+ Tregs in muscle tissue in our study was increased after treatment of abatacept, 
however, the suppressive functions of Tregs were not tested. The effect of abatacept on the 
functions of Tregs differ between different resident tissues and different autoimmune 
conditions. Thus, whether Tregs have an effect in the mechanism of action of abatacept in 
muscle tissue of patients with DM and PM still needs to be explored. We also searched for 
clinical or laboratory variables that could predict treatment response, but without success.  
5.1.5 Effect of abatacept treatment on phenotypes of T cells in blood samples 
We used CyTOF, a mass cytometry technique, to investigate phenotypic differences of 
peripheral T and B cells of DM and PM patients with repeated blood samples taken before and 
after 6 months of active abatacept treatment, but no significant differences were found on group 
level.  
CD28null T cells and FOXP3+ T regulatory cells are two distinct subsets of T cells present in 
both muscle and blood samples of DM and PM patients. The cytotoxic activity of CD28null T 
cells and the suppressive capacity of FOXP3+ T regulatory cells may play a role in the 
pathogenesis of DM and PM. In a previous study, the frequency of CD28null T cells was higher 
while the frequency of FOXP3+ T regulatory cells was lower in blood samples of DM and PM 
patients compared to healthy controls by using flow cytometry [172]. We did not find any 
changes on the frequency of these two groups of cells in the circulation after 6 months of 
treatment with abatacept, measured by CyTOF.  
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Twenty-nine antibodies focusing on markers of T cells were tested by using CyTOF. Multiple 
combinations of these markers provide possibilities to identify conventional T cell subgroups 
and also some novel subsets not reported before (Figure 6), indicating the power of CyTOF as 
a discovery tool. The analysis of large amounts of data is a big challenge to the users. Several 
specific analytical methods with different functions are recommended. T-SNE map and 
SPADE were applied to get the overview of the multidimensional data of CyTOF, and Citrus 
was used to elucidate cell groups predicting differences in different time points. By using 
several methods to analyze CyTOF data, we did not observe any treatment-induced changes 
on group level. The reasons may be the clinical heterogeneity of patients enrolled, the steady 
state of PBMCs without stimulation, and/or the small number of patients involved.  
 
Figure 6. The clustering tree from SPADE (CyTOF analytical tool), where edges represent 
similarity and nodes are clusters, with area proportional to the average cell frequency among 
samples. The colors in the background show manually defined groups of SPADE clusters. 
 
5.1.6 The correlation of cell phenotypes expressed in muscle and blood 
samples compared to clinical outcome 
FOXP3+ T regulatory cells not only suppress the inflammation in muscle tissue, but also exert 
the recovery of muscle fibers. In two different mouse models, Tregs inhibited the injury of 
muscle fibers [173] and promoted the proliferation of satellite cells leading to the regeneration 
of muscle fibers [174]. In our study (Paper I), the muscle strength of DM and PM patients 
improved after the 6 months of abatacept treatment. Although we did not find any correlation 
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between the number of FOXP3+ Tregs in muscle tissue and MMT-8 of DM and PM patients 
before and after 6 months of abatacept treatment, FOXP3+ T regulatory cells in muscle tissue 
may still be a potential regulator of the improvement of muscle strength. 
A positive correlation between the ratio of frequency of CD4+ and CD8+ T cells (CD4/CD8) in 
peripheral blood before active abatacept treatment (r=0.74, P=0.0038) with FI-2 score 
improvement was observed. A positive correlation between CD4/CD8 ratio and FI-2 
improvement was also found after treatment (r=0.69, P=0.013). FI-2 indicates muscle 
endurance of DM and PM patients [175]. The ratio of CD4+/CD8+ T cells in peripheral blood 
samples in RA patients after 4 weeks of abatacept treatment was a predictor of the efficacy 
(DAS28-CRP) of abatacept treatment [176]. This suggests that the ratio of CD4/CD8 in 
circulation might also be a potential parameter to measure the beneficial effects of abatacept 
on muscle endurance of DM and PM patients. 
5.2 THE HOST DEFENSE PEPTIDE LL-37 A POSSIBLE INDUCER OF THE TYPE 
I INTERFERON SYSTEM IN PATIENTS WITH POLYMYOSITIS AND 
DERMATOMYOSITIS 
           (Project 3) 
5.2.1 Expression pattern of LL-37, CD66b, BDCA2, and MxA in muscle and 
skin tissue of DM and PM patients 
LL-37, CD66b, BDCA2, and MxA were present in corresponding areas of consecutive slides 
of muscle and skin biopsies from DM and PM patients. The expression of LL-37, CD66b, 
BDCA2, and MxA in muscle biopsies was similar in patients with short and long disease 
duration (Figure 7A-D). LL-37 also co-localized with CD66b+ neutrophils in both muscle and 
skin biopsies of DM and PM patients, identified by using double fluorescence staining. 
These results support our hypothesis that CD66b+ neutrophils express LL-37, which may 
stimulate BDCA2+ pDCs to produce type І IFN (MxA) in muscle and skin tissue of DM and 
PM patients, regardless of short time or long time of disease duration. But these are 
immunohistochemistry staining results, in vitro cell stimulation experiments are needed to 
prove this hypothesis.  
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Figure 7. The comparison of expression of (A) LL-37, (B, E) CD66b, and (C) BDCA-2 
presented by the number of positively stained cells per mm2 and (D) MxA presented as 
percentage of positively stained areas out of the whole tissue section in muscle biopsies 
between patients with short disease duration and long disease duration.  
 
5.2.2 Expression of CD66b and MxA in myositis patients with and without 
autoantibodies targeting RNA-binding proteins 
Autoantibodies targeting RNA-binding proteins were present in one DM and four PM patients 
but negative in seven patients (5 DM, 2 PM). The number of CD66b+ cells (neutrophils) in 
muscle biopsy of patients with autoantibodies targeting RNA-binding proteins were 
significantly lower compared to seronegative patients (P<0.05, Figure 8). The number of 
CD66b+ cells showed a positive correlation to the expression of MxA (type I IFN secreted 
protein) in patients without autoantibodies targeting RNA-binding proteins (r=0.79, P<0.05). 
Type І IFN signature was found increased in muscle tissue and blood samples of DM and PM 
patients [49]. Autoantibodies targeting RNA-binding proteins were associated with expression 
of type І IFN in patients with SLE [177], which was also observed in myositis patients with 
autoantibodies [91], and experimental data suggested that immune complex containing 
antibodies targeting RNA-binding proteins could induce type І IFN production from pDCs. 
However, an increased expression of MxA, indicating type I IFN activity in muscle tissue, was 
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also seen in DM patients without autoantibodies, suggesting the presence of alternative 
inducers of type І IFN in myositis patients [95]. The higher number of CD66b+ neutrophils and 
the association between neutrophils and MxA in patients negative of autoantibodies targeting 
RNA-binding proteins could indicate that LL-37 is a potential alternative pathway to induce 
the elevated type І IFN in myositis patients without these autoantibodies. Another observation 
from this study was the presence of neutrophils in muscle and skin samples. Neutrophils have 
rarely been reported in muscle biopsies before, whether this can be explained by different 
staining protocols or that they have not been looked for in earlier studies is not known. Whether 
neutrophils have a role in the pathogenesis of patients with myositis could not be answered by 
our study. 
 
 
Figure 8. The expression of CD66b in muscle tissue of patients with autoantibodies targeting 
RNA-binding proteins compared to patients negative for autoantibodies targeting RNA-
binding proteins. *P<0.05.  
 
5.3 MUSCLE BIOPSY FEATURES IN REPEATED BIOPSIES AND RESPONSE 
TO TREATMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY 
MYOPATHY – A PILOT STUDY 
        (Project 4)  
As there is a variety of clinical outcome in patients with myositis to glucocorticoids and 
immunosuppressive agents, it is important to identify predictors of treatment response of the 
patients. Skeletal muscle is the major target tissue in myositis. Thus, we investigated the 
expression of different molecules present in muscle tissue of myositis patients to identify 
possible markers to predict response to conventional immunosuppressive treatment.  
5.3.1 Expression of CD68, CD163, and IL-15 in muscle biopsies of responders 
and non-responders pre- and post- treatment 
In the pre-treatment biopsies, the expression of CD68 of responders was numerically higher 
than in non-responders (median (IQR), 0.50 (0.16-1.58)-0.39 (0.05-0.66)), but there was no 
statistically significant difference of the expression of CD68 between responders and non-
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responders. The expression of CD68 in the repeated muscle biopsies in responders was 
significantly lower than in non-responders after approximately 1-year treatment, although 
follow-up biopsies in responders were only available from three responders (P<0.05, median 
(IQR), 0.13 (0.04-0.13)-0.31 (0.19-0.37)). The expression of CD68 showed a within-group 
trend towards decrease after treatment in responders (median (IQR), 0.87 (0.21-3.71)-0.13 
(0.04-0.13)), but there were no trends in non-responders. The same pattern was observed for 
the expression of CD163 and IL-15. In the pre-treatment biopsies, there was a moderate 
negative correlation between CD68 expression and MMT-8 (r =-0.5641, P=0.0454).  
CD68+ and CD163+ macrophages are commonly observed in muscle biopsies of most myositis 
patients. IL-15 secreted by macrophages is an important cytokine activating T cells. The 
reduction of macrophages and IL-15 expression in muscle tissue of patients with myositis after 
treatment is consistent with previously observed results [178]. The expression of CD68 in pre-
treatment muscle biopsies correlated with muscle strength presented by MMT-8. A previous 
study showed that the expression of IL-15 associated with the improvement of muscle 
endurance measured by FI-2 [178]. But we did not observe this association in our study, maybe 
due to the low number of patients. Conclusively, CD68 expression in muscle tissue, particularly 
a reduction after treatment, seems to be a potential marker to predict clinical long-term outcome 
of conventional immunosuppressive treatment, especially muscle performance. Notably, the T 
cells did not decrease after treatment in the repeated muscle biopsy. This might due to the low 
number of patients or suggest a need for more T cell targeting therapies in patients with T cells 
in infiltrates in muscle tissue. 
5.3.2 Frequency of monocytes in blood samples of responders and non-
responders pre- and post- treatment 
Repeated blood samples were available from five patients, 3 responders and 2 non-responders. 
Classical monocytes, intermediate monocytes, and non-classical monocytes were present in the 
blood samples of the five patients. The expression of the intermediate subset of monocytes 
showed a trend to increase in responders whereas an opposite trend was observed in non-
responders after treatment. Before treatment the fraction of intermediate subset was lower in 
responders than in non-responders, but the opposite was observed after treatment. 
Intermediate monocytes are associated with inflammatory processes in healthy controls and in 
individuals with autoimmune diseases [179, 180]. A negative correlation between frequency 
of intermediate monocytes and reduction of disease activity after methotrexate treatment was 
found in patients with RA suggesting that the frequency of intermediate monocytes is 
predictive to methotrexate therapy [181]. We only tested the intermediate monocytes in five 
patients without statistically significant results. As macrophages are commonly found in 
muscle biopsies of myositis patients, and considering the inflammation-related regulatory 
function exerted by intermediate monocytes, it would be interesting to investigate the 
frequency of intermediate monocytes in relation to treatment response in a larger cohort of 
patients with myositis. 
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6 CONCLUSIONS AND PERSPECTIVES 
The immunological mechanisms of myositis have been generally accepted as an interaction 
between the innate immunity and the adaptive immunity. In my research, Project 1 and Project 
2 mainly focused on adaptive immunity and Project 3 was mainly related to innate immunity. 
In project 4, we investigated if some of the markers involved in both the innate and adaptive 
immunity could predict the clinical outcome of myositis patients. In our projects, we found that 
abatacpet is a potential new treatment for myositis with improved muscle performance of 
patients, LL-37 might induce the upregulation of type І IFN, and the effects of conventional 
immunosuppressive treatment on CD68+ macrophages in muscle biopsies might be predictive 
to the clinical long-term outcome in patients with myositis.   
A few randomized and controlled trials performed during recent years have reported some 
efficacy of biological treatments on myositis. However, the therapeutic effects are still not 
satisfactory. New therapies are still needed. In Project 1 and 2, we investigated the effects of 
a selectively co-stimulation modulator-abatacept (CTLA-4Ig) on clinical parameters, 
molecular expressions in muscle tissue, and phenotypes of T cells in blood samples of DM and 
PM patients. The clinical evaluation showed beneficial effects of abatacept treatment in almost 
half of the previously treatment resistant patients with myositis and accepted tolerance. The 
results provide support for a role of T cells in a subset of patients with DM and PM. 
As the modulator of co-stimulation of T cells, abatacept is a T cell activation blocking agent. 
We also aimed to get a hint of the important roles of T cells in the pathogenesis of myositis by 
investigating the molecular expression of T cells in muscle tissue as well as the phenotypes of 
T cells in circulation. The number of FOXP3+ Tregs in muscle tissue increased significantly in 
a subgroup of patients together with improved muscle strength evaluated by MMT-8 after 
abatacept treatment for 6 months. Therefore, in this subgroup of patients treatment with 
abatacept looks promising as it appears to improve the muscle strength. In addition, we 
conclude that FOXP3+ Tregs seemed to be sensitive to the modulation of abatacept treatment, 
hence, highlighting the importance of FOXP3+ Tregs in the pathogenesis of DM and PM. In 
our study, repeated muscle biopsies were only available for six patients. Thus, the increased 
number of Tregs observed in muscle biopsies of abatacept-treated patients needs to be 
confirmed in a larger cohort with a higher number of repeated muscle biopsies. The observation 
from the repeated muscle biopsies together with the clinical improvement of muscle strength 
supports the hypothesis that abatacept could be a potential biological treatment for a subgroup 
of patients with myositis. However, a larger, randomized, controlled and placebo trial is 
important to confirm the efficacy and safety of abatacept treatment in myositis and the trial is 
ongoing. Furthermore, in a larger trial, biomarkers that could predict response to abatacept 
treatment among patients with myositis may be identified. 
In Project 2, we did not see any statistically significant changes of phenotypes of T cells in 
circulation after compared to before abatacept treatment by using CyTOF. However, we found 
a positive correlation between the ratio of CD4+/CD8+ T cells in circulation, both at baseline 
and after treatment, with a measure of muscle performance, FI-2 score improvement, 
suggesting that CD4/CD8 ratio in circulation may be a predictor of the improvement of muscle 
endurance of myositis patients with abatacept treatment. Again, more patients are required in 
a larger trial to confirm these results. The Citrus (CyTOF analytical tool) results showed that 
FOXP3+ and CD28null T cell subsets were sensitive to the abatacept treatment in the circulation, 
however, due to high false discovery rate (FDR) the changes did not reach any significant 
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difference. For future trials, the markers of FOXP3+ and CD28null T cell subsets should be paid 
more attention. Another parallel conventional method, like flow cytometry, is also 
recommended to be taken into consideration to confirm the results from the CyTOF analyses. 
Both innate and adaptive immunity are involved in the immune mechanism of myositis. Type 
І IFN is an important member of innate immunity and may also be an important cytokine in 
the pathogenesis of myositis. In Project 3, we provide evidence to support our hypothesis that 
LL-37 expressed by neutrophils may be an inducer of Type І IFN by stimulating pDCs. But 
further investigation is required to confirm these results. In vitro experiments with the co-
culture of these cells taken from patients are recommended. 
In Project 4, we tested several molecules to identify markers that could predict the clinical 
outcome of conventional treatment. The staining of inflammatory cells with 
immunohistochemistry in repeated muscle biopsies taken within the first year of treatment 
together with evaluation of disease activity and muscle strength may be a way to predict 
prognosis for recovery of muscle performance. CD68 may be a promising predictive marker, 
but this needs to be confirmed in a larger study. 
Myositis is a rare group of autoimmune diseases leading to difficulties to recruit large number 
of patients for randomized and controlled studies. The high heterogeneity of myositis patients 
also brings difficulties to reach statistically significant results at group level. Therefore 
multicenter collaborations are important like we did in my first two projects. Still it took a long 
time to recruit the 20 patients in this pilot study. For future studies more homogenous subgroups 
e.g. selected by autoantibody profiles could be considered. A strength of our studies is the 
combination of detailed clinical longitudinal data with repeated muscle biopsies and blood 
samples. However, the muscle biopsy samples, are often small especially follow-up muscle 
biopsies, limiting the number of investigations to perform on each specimen which is a 
limitation for studies using immunohistochemistry or immunofluorescence staining. These are 
general limitations of all my four studies. New technologies where several molecules could be 
investigated in the same biopsy sample would be interesting to test in future studies, as well as 
investigations transcripts in single cells in tissue samples. Even though our cohorts are small, 
we have collected different types of tissue samples from patients and included different 
molecular markers to investigate the effects of biological treatment on myositis, the underlying 
pathogenesis of myositis, and the prognosis prediction of myositis. 
In conclusion, our findings strengthen the critical roles of innate and adaptive immune response 
in the pathogenesis of myositis by investigations from different perspectives and in different 
cohorts. In addition, there are individual differences regarding molecular patterns among 
patients with myositis, which needs to be taken into account in future studies. Finally, our data 
may provide some clues on how to develop novel and effective therapies for patients with 
myositis.  
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